annual report value innovationf amount eur million indicate change net sale region europe america asia australia africa business human pharmaceutical animal health biopharmaceutical discontinue operation research development personnel expense average number employee operate income operating income net sale group profit loss net sale group equity return group equity investment tangible asset depreciation tangible asset product human pharmaceutical product animal health net sale million eur change net sale million eur change spiriva nexgard pradaxa frontline jardiance ingelvac ciroflex trajenta jentadueto heartgard core leitbild group management report consolidate financial statement product portfolio company improve health quality life patient goal researchdriven pharmaceutical company boehringer ingelheim focus disease satisfactory treatment option exist date company concentrate develop inn ovative therapy extend patient live animal health boehringer ingelheim stand advanced prevention familyowne establish boehringer ingelheim pharmaceutical industry company employee create value innovation daily business area human pharmaceutical animal health biopharmaceutical boehringer ingelheim generate net sale billion euro expenditure billion euro correspond cent net sale familyowne company boehringer ingelheim plan generation focus longterm success shortterm profit company aim organic growth resource simultaneous openness partnership strategic alliance research boehringer ingelheim naturally adopt responsibility mankind environmentc core leitbild shareholder perspective key aspect corporate body group management report information group report economic position report opportunitie risk report expect development consolidate financial statement overview select consolidated company consolidate balance sheet consolidated profit loss statement cash flow statement statement change group equity note consolidate financial statement independent auditor report product portfolio human pharmaceutical respiratory disease cardiovascular metabolic disease oncology disease central nervous system infectious disease tiergesundheit livestock swine livestock cattleruminant livestock poultry veterinary public health vph companion animal horse companion animal pet sharehlder perspective shareholder perspective shareholder perspective successful year boehringer ingelheim success mean reach patient deliver significant contribution human animal health favourable figure company document annual report testify success primary objective remain maintain boehringer ingelheim indepen dence order sustainable continue remain competitive need innovation readiness invest competition average research development production innovative medicine follow knowledge time mirror trust place boehringer ingelheim employee high degree commitment decisive success share guide principle leitbild goal improve health human animal bind worldwide individuality characterise culture value stand familyowned company boehringer ingelheim help maintain independence express thank employee contribute great engagement effort realise corporate goal sign christian boehringer chairman shareholder committeet allan hillgrove michel pairet hubertus von baumbacht michael schmelmer andreas neumann joachim hasenmai key aspect employee worldwide share enthusiasm task improve health human animal innovation therapeutic breakthrough today want tell realise share vision result able achieve past year year successful boehringer ingelheim reason focus innovation large number research project currently human pharmaceutical pursue approach want therapeutic class indication decisive conduct research area unmet medical need patient dependent innovation focus principle foundation success boehringer ingelheim decade provide basis growth human pharmaceutical business year expiry market exclusivity mark impact development big product overall able grow line local market frequently outgrow considerably thank great therapeutic progress offer new pro duct ofev jardiance animal health area conclude integration process merge organisation prioritise customer need ahead optimisation enable exceed market growth year new structure biopharmaceutical business develop favourably particular progress expand capacity vienna austria today visible large extent numerous partnership reinforce innovative core equally business area value chain show specific competence party combine boehringer ingelheim special capability translate patient benefit accom panye magazine highlight transformation take detailed look possibili tie digitalisation offer dear reader past financial year successful boehringer ingelheim charac terise continual change previous year basis trust customer partner especially commitment employee sense responsibility entrepreneurial spirit help remain competitive deserve thank sign sign sign hubertus von baumbach joachim hasenmai allan hillgrove sign sign sign andreas neumann michel pairet michael schmelmer corporate body shareholder committee board manage director christian boehringer hubertus von baumbach chairman shareholders committee chairman board manage director christoph boehringer joachim hasenmai member board manage director erich von baumbach animal health isabel boehringer allan hillgrove member board manage director mathias boehringer human pharma prof andreas barner andreas neumann member board manage director human resource advisory board michel pairet member board manage director egbert appel innovation chairman advisory board trustee martin hilti family trust michael schmelmer president hilti foundation member board manage director finance nikolaus von bomhard chairman board management mnchener rckversicherungsgesellschaft andreas kreimeyer member board executive director research executive director basf jan rinnert chairman board manage director heraeus hold gmbhpage tpage information group group business model research development production occupational safety environmental protection employee report social responsibility report economic position macroeconomic environment earning position development business financial position net asset position report opportunitie risk opportunitie risk management individual risk overall statement risk situation report expect development troper tnemeganam puorg boehringer ingelheim annual report group management report information group group business model year boehringer ingelheim pursue goal improve preserve quality life health human animal headquarter ingelheim rhein germany com pany familyowne found lead company world wide industry germany researchintensive company boehringer ingelheim concentrate particular research medicine offer therapy disease satisfactory treatment option currently unavailable provide entire value chain start reasearch development production commercialisation product boehringer ingelheim operate global level employee area human pharmaceutical animal health biopharmaceutical generate net sale eur billion human pharmaceutical company medicine standard treatment therapeutic area represent core focus boehringer ingelheim activity integration merial follow transaction january contain swap boehringer ingelheim consumer successfully complete health care business sanofis animal health business merial integration new compa ny successfully complete merger boehringer ingelheim exist animal health activity merial company animal health business market leader germany global level secondlarg provider veterinary vaccine medicine unmesta tszearllsees abchy besuchsifntene sin group eur million biopharmaceutical sale eur million eur million animal health human pharmaceutical eur million eur million group management report net sale region eur million europe asia australia africa aaa americas boehringer ingelheim continue expand exist product portfolio organic growth include cooperation external partner recent acquisition company global research network expand country major facility germany biberach han ingelheim ridgefield connecticut duluth georgia joseph missouri austria vienna japan kobe france lyon company big revenue contributor human pharmaceutical business spiriva big spiriva treat chronic obstructive pulmonary disease copd asthma revenue contributor follow product significant contribution boehringer ingelheim success pradaxa prevent stroke patient atrial fibrillation prevention treatment thromboembolic disorder type diabete product jardiance winner prix galien inter national innovative pharmaceutical product trajenta medicine ofev medicine introduce offer people rare fatal respiratory dis ease idiopathic pulmonary fibrosis ipf time treatment option company animal health business antiparasitic nexgard strong product term net sale antiparasitic heartgard frontline establish swine vaccine ingelvac circoflex treat porcine circovirus type play key role success company animal health business biopharmaceutical business important growth area boehringer ingelheim boehringer ingelheim biopharmaceutical activity comprise manufacture ownbrand market able product actilyse metalyse praxbind world lead com panie process development commercial production biopharmaceutical thirdparty industrial customer laicnanif detadilosnoc stnemetat boehringer ingelheim annual report financial year boehringer ingelheim achieve majority sale america europe regions region asiaaustraliaafrica aaa strategic significance group future growth make sale big market usa japan germany account sale research development line mission statement boehringer ingelheim goal research develop innovative medicine therapie treatment disease currently satisfactory treatment available key emphasis develop pharmaceutical new approach therapy prevent detect treat chronic disease effectively focus make major contribution area need treatment high take lead position human pharmaceutical business field animal health research development expenditure eur million net sale human pharmaceutical expenditure eur million human pharmaceutical net sale average number employee investment tangible asset investment infrastructure eur million rely partnership academic institution biotech company public research institu tion global research network comprise facility different country world field development project technology research activ itie supplement important cooperation licence agreement boehringer ingelheim continue expand research network acquisition viratherapeutic gmbh represent significant addition immunooncological therapy base use oncolytic virus area cardiovascular study examine effect empagliflozin launch cooperation eli lilly company portfolio broad supplement partnership key component boehringer ingelheim innovation strategy complement innovative prowess evidence boehringer ingelheim successful collaboration party see online portal opnme give researcher worldwide opportu nity order molecule boehringer ingelheim use fear infringe patent researcher unique opportunity start experiment continue research addition joint research project develop new finding drug development generate group management report site animal health human pharmaceutical americas europe asia oceania brazil germany australia paulnia biberach sydney hanover mexico ingelheim china guadalajara katharinenhofrohrdorf shanghai taizhou usa denmark ame kalundborg japan athens colbert kobe duluth france tokyo fulton lyon gainesville saint vulbas new zealand north brunswick auckland ridgefield italy saint joseph milan sioux center netherlands lelystad austria vienna second year existence boehringer ingelheim digital laboratory employee digital laboratory expert digital technology currently work innovative digital product year innovation driver successfully hand respective business past year petpro con nect app connect pet owner vet usa collaboration platform research er ntc studio boehringer ingelheim activity basis company sustainable success inno vative capability play key role group positive business development past year inhouse supplement external cooperation partnership continue priority future laicnanif detadilosnoc stnemetat boehringer ingelheim annual report financial year employ average people facility total eur billion invest new medicine correspond group net sale slightly level expect human pharmaceutical respiratory century commit improve life people living disease respiratory disease scientific research new therapeutic concept help patient need continue high importance boehringer ingelheim focus area chronic obstructive pulmonary disease copd cystic fibrosis idiopathic pulmonary fibrosis ipf systemic sclerosis interstitial lung disease sscild form progressive fibrose interstitial lung disease pfild early result landmark dynagito trial publish lancet respiratory datum week trial people copd tiotropiumolodaterol lower rate moderatetosevere exacerbation compare tiotropium monotherapy result contribute understand copd exacerbation role dual combination bronchodilator lamalaba therapy management copd focus topic importance physical activity people live copd number study complete publish investigate effect tiotropumolodaterol compare tiotropium monotherapy physical activity relate endpoint end year start receive national approval new enhance respimat inhaler launch european country start quarter european respiratory society international congress present final datum important trial idiopathic pulmonary fibrosis ipf inpulsison trial instage trial result inpulsison indicate safety efficacy nintedanib ipf maintain year consistent prior finding inpulsis study programme instage trial show efficacy safety nintedanib patient ipf severe impair ment gas exchange usually exclude clinical trial consistent observed patient advanced disease early trial trial publish highranke med ical journal lancet respiratory new england journal medicine respectively addi tion communicate new scientific datum key effort raise awareness need diagnose treat ipf early possible stakeholder partner remain key challenge affect patient boehringer ingelheim found member open source image consortium osic statement commitment advance science support innovation ben efit patient goal osic develop digital imaging biomarker accurate imagingbase diagnosis prognosis prediction response therapy ipf fibrose interstitial lung disease ild group management report scleroderma systemic sclerosis ssc continue effort support patient create awareness rare disease scleroderma campaign senscis trial inve tigate safety efficacy nintedanib patient systemic sclerosisassociate ild complete patient recruit large randomised placebo control clinical trial ssc date result present inbuild trial evaluate efficacy safety nintedanib week patient pro gressive fibrose interstitial lung disease pfild ongoing trial include range patient diagnose interstitial lung disease ipf exhibit similar progressive fibrosing phenotype deterioration respiratory symptom lung function worsen fibrosis chest image irrespective underlie diagnosis unique basket approach make inbuild trial include patient different underlying disease varied chronic hyper sensitivity pneumonitis rheumatoid arthritis associate ild sarcoidosis approach base underlying hypothesis response lung injury patient include development fibrosis progressive selfsustaine independent initiate trigger result expect course boehringer ingelheim commit fight cancer provide patient new treatment oncology option dedicate collaborate oncology community share journey deliver lead science goal firstinclass treatment breakthrough potential transform live patient help win fight cancer focus discover develop accelerate novel therapeutic approach address unmet need lung gastrointestinal cer end conduct target research therapy immunooncology product intelligent combination approach offer great chance success fight cancer successfully advance research programme clinical development strengthen oncology portfolio actively seek scientific collaboration inno vative partnership strategic acquisition goal improve understand cancer transform patient live commitment innovation result important treat ment lung cancer afatinib giotrifgilotrif nintedanib vargatef afatinib giotrifgilotrif secondgeneration egfr inhibitor treatment specific type nonsmall cell lung cancer nsclc patient metastatic nsclc squamous histology available patient standard care market approve indication result giotag realworld study investigate use frontline afatinib follow nextline target treatment extend chemotherapyfree treatment time patient publish study show afatinib giotrifgilotrif fol low osimertinib thirdgeneration egfr inhibitor provide median month chemo therapyfree regimen patient egfr mutationpositive nsclc result add com prehensive luxlung trial programme afatinib trial include head head randomise trial versus firstgeneration treatment boehringer ingelheim second market cancer drug vargatef nintedanib treatment advanced nonsmall cell lung cancer nsclc combination docetaxel patient pre viously treat chemotherapy december result realworld study vargado show nintedanib plus docetaxel option failure immunotherapy patient nintedanib combination chemotherapy investigate patient malig nant pleural mesothelioma mpm epitheloid histology rare aggressive type cancer laicnanif detadilosnoc stnemetat boehringer ingelheim annual report strongly associate exposure asbestos datum respective phase iii trial lumemeso present show nintedanib combination standard chemotherapy extend progressionfree survival patient mpm cardiovascular boehringer ingelheim therapeutic area cardiovascular metabolic disease contain metabolic disease companys core product diabetes portfolio specifically jardiance empagliflozin important research datum publish range new clinical trial collaboration announce march boehringer ingelheim diabete alliance partner eli lilly announce plan expand clinical trial programme empagliflozin chronic heart failure emperial rial trial evaluate effect empagliflozin exercise ability heart failure symptom people chronic heart failure independent type diabete april diabetes alliance initiate empakidney clinical trial investigate effect empagliflozin progression kidney disease occurrence cardiovascular death peo ple establish chronic kidney disease diabete study independently conduct analysed report medical research council population health research unit university oxford mrc phru summer datum ease phase iii programme investigate use empagliflozin combination insulin therapy adult type diabe tes publish randomise control trial meet primary endpoint base total ity ease datum boehringer ingelheim initiate regulatory discussion empagliflozin adjunct insulin adult type diabete european medicine agency ema committee medicinal product human use chmp issue positive opinion july update label jardiance empagliflozin synjardy empagliflozin metformin glyxambi empagliflozin linagliptin include additional important datum landmark empareg outcome trial heart failure kidney endpoint label include result relative risk reduction hospitalisation heart failure relative risk reduction newonset worsen kidney disease empagliflozin compare placebo people type diabete establish cardiovascular disease european association study diabetes easd congress october result carmelina cardiovascular outcome trial dpp inhibitor linagliptin trajenta present carmelina study impact linagliptin cardiovascular kid ney safety adult type diabete high risk heart andor kidney disease study meet primary endpoint linagliptin demonstrate similar cardiovascular safety profile compare placebo add standard care carmelina include key secondary composite endpoint show similar kidney safety profile compare placebo result second cardiovascular outcome trial carolina expect carolina evaluates impact treatment linagliptin compare sulphonylurea glimepiride standard care cardiovascular safety patient early type diabete increase cardiovascular risk estab lishe cardiovascular complication group management report shortly easd congress american diabetes association ada easd publish consensus report recommend sglt inhibitor empagliflozin help manage cardiovas cular outcomes patient type diabete empagliflozin sglt inhibitor recom mend ada standard medical care diabetes reduce risk cardiovascular death people type diabete establish cardiovascular disease follow announce ment american college cardiology acc publish new expert consensus decision pathway ecdp recommend empagliflozin prefer sglt inhibitor prove benefit reduce risk cardiovascular death adult type diabete establish cardiovascular disease worldwide treatment guideline update include finding empareg outcome trial endorsement type diabetes treatment prove cardiovascular benefit october journal circulation publish analysis base datum empareg outcome trial suggest treatment empagliflozin positively impact life expectancy adult type diabete establish cardiovascular disease actuarial method assume demonstrate beneficial effect empagliflozin remain consistent longterm use empagliflozin estimate extend life expectancy year average depend age compare placebo american heart association aha scientific session november initial effectiveness result realworld evidence study empagliflozin emprise present reinforce clinical result landmark empareg outcome trial finally conclude highly successful year diabete product jardiance empagliflozin award international prix galien good pharmaceutical product award prestig ious honour field pharmaceutical research innovation recognise outstanding effort achievement pharmaceutical successful year pradaxa october company present primary result key trial respectesus respect cvtat world stroke congress montreal canada respectesus trial investigate dabigatran etexilate versus acetylsalicylic acid asa result trial expect publish primary analysis contribute scientific communitys understanding disease add wealth evidence support ing establish safety profile pradaxa important neuropsychiatric disease schizophrenia alzheimer disease disease depression continue centre boehringer ingelheim research central nervous central nervous system disease company institution pull cns project past year system cns reason player field setback frequent success boehringer ingelheim remain true motto commitment stop opti mistic develop effective therapy treatment neuropsychiatric disease laicnanif detadilosnoc stnemetat boehringer ingelheim annual report highly complex disease like schizophrenia focus investigate impaired glutama tergic signal pathway present range cns disease base finding clinical trial schizophrenia investigate particular specific mechanism action prevent deterioration psychotic episode prevent relapse schizophrenia study effect glyt inhibition cognitive impairment alzheimer disease schizo phrenia track expect phase clinical result beyon clinical trial depression investigate effect substance influence hyperactivity certain brain region responsible impaired processing negative stimulus start substance investigate early stage development immunology boehringer ingelheim continuously develop immunology activity year ramp capacity series dermatological gastroenterological indication initial clinical testing result publish september field dermatology suggest positive therapeutic potential active substance interleukin receptor antagonist rare form psoriasis know generalise pustular psoriasis patient clearly visible inflammatory skin disease palmoplantar pustulosis ppp neurodermitis atopic dermatitis frequently face considerable disruption live skin change painful visible series active substance rorgamma inhibitor currently clinical development stage show initial sign offer strong therapeutic potential patient immunological disease boehringer ingelheim development programme include substance treatment chronic inflammatory bowel disease crohns disease ulcerative colitis lupu nephritis strong unmet medical need effective therapy year development substance risankizumab treatment psoriasis originally result research activity complete partnership abbvie abbvie submit substance regulatory authority development marketing partner ship abbvie offer good mean ensure interleukin inhibitor emerge boehringer ingelheim research programme available great possible number patient broadbase pipeline substantial investment immunology boehringer ingelheim expects significantly contribute well treatment patient immune disease foreseeable future assume sole responsibility development marketing activity group management report animal health work field animal health boehringer ingelheim concentrate innovative vaccine antiparasitic protection livestock pet pharmaceutical product treatment chronic disease facilities europe asia oceania north central south america focus research new drug development future therapeutic solution vaccine base local pathogen pathogen variant imperative present key market region local production facility past year invest approximately eur million new plant expansion exist facility lyon portedesalpe france complete construction eur million research building employee order bring activity vaccine production single facility milestone spatial consolidation research activity china eur million investment expansion research centre investment demonstrate commitment strengthen animal health mean innovative preventive medicine intention sustainably expand lead position field initiate clinical study worldwide receive product authorisation addition internal analyse external project product integrate portfolio appropriate obtaining approval expand geographical distri bution exist product important aspect activity biopharmaceutical decide pursue biosimilar activity include potential partnership market end development activity market concentrate launch approve biosimilar cyltezo adalimumabadbm market laicnanif detadilosnoc stnemetat boehringer ingelheim annual report production facility animal health human pharmaceutical biopharmaceutical bio americas europe italy asia oceania brazil denmark fornovo china itapecerica kalundborg noventa nanchang paulnia shanghai bio germany netherlands taizhou mexico biberach bio lelystad guadalajara dortmund indonesia xochimilco ingelheim austria bogor vienna bio puerto rico france japan barceloneta lyon spain yamagata saintherblon malgrat usa toulouse sant cugat new zealand athens auckland columbus greece united kingdom fremont bio koropi pirbright gainesville joseph production human pharmaceutical human pharmaceutical business production responsible reliable supply innova tive topquality medicine competitive price patient customer ongoing development company internal production facility strategic cooperation external manufac turer establish modern flexible market supply network encompass entire value chain supplier start material worldwide logistic distribution finish pharma ceutical product group management report global network include boehringer ingelheim plant country group biopharmaceutical facility plant manufacture active pharmaceutical ingredient plant manufacture finished pharmaceutical product facility boehringer ingelheim production facility concentrate product strategic country human importance company stateoftheart case unique manufacturing tech pharmaceutical nologie partnership external manufacturer expand production capacity focus prod uct far advanced term life cycle scope company redesign network increase amount produce com pany antidiabetic product portfolio transfer facility world assume increasingly important role instance production capacity increase active pharmaceutical ingredient fornovo italy finish pharmaceutical product koropi greece xochimilco mexico company initiate additional important investment development transformation capacitie internal external network ingelheim headquarters company begin implement key investment industrialisa tion newly develop medicine initial market supply medicine sant cugat facility spain company progress construction plant supply market respimat technologybase inhalation medicine time end product life cycle aggrenox company close biberach site dedicate production plant alongside continue development company production network ongoing development value chain management current area focus implementation company supply chain strategy set motion process transformation span entire value chain supplier customer endtoend goal highly integrate flexible delivery chain fully transparent efficiently control modern digital technology animal health follow acquisition merial team company work create environment promise future success boehringer ingelheim animal health operate network facility country dedicate manufacture vaccine animal health facility finish pharmaceutical product nutraceutical industrial setup complement con country tract manufacturer primarily north central america europe define new network strategy order balance internal external production subsequently integra tion merial focus core product alignment business requirement addition production facility paulnia brazil past year invest new production line strong revenue contributor nexgard barceloneta puerto rico facility produc tion vaccine footandmouth disease expand global level boehringer ingelheim establish collaboration chinese partner aim triplication production soughtafter vaccine laicnanif detadilosnoc stnemetat boehringer ingelheim annual report biopharmaceutical lead boehringer ingelheim pursue biopharmaceutical activity facility biberach germany company vienna austria fremont california usa shanghai china comprise manufacture industrial customer ownbrand marketable product actilyse metalyse praxbind manufacture biopharmaceutical clinical testing world market leader process develop ment launch preparation commercial production biopharmaceutical thirdparty industrial customer pharmaceutical company innovative biotech firm client boehringer ingelheim biopharmaceutical business boehringer ingelheim cover entire biophar maceutical value chain genetic development production cell follow manufacture active substance filling finish pharmaceutical product product launch global market supply see overall increase use capacity network industrialscale production facility product boehringer ingelheim fulfil biberach germany facility increase level market demand actilyse chinese market particular com pany facility fremont california usa largescale bioreactor launch market product customer transfer possible meet rise product demand network biberach germany fremont california usa largescale cell culture plant biberach germany largescale microbial plant vienna aus tria customer product successfully approve international authority expansion project new industrialscale biopharmaceutical production facility boehringer ingel heim site vienna austria reach milestone toppingout ceremony facil ity take place autumn company commercial filling facility shanghai china successfully operation local market country outside china production delivery begin schedule gmp hospital product finish pharmaceutical product addition application approval customer product chinese authority successfully complete important milestone term chinese authority recognition shanghai facility contract manufacturer cmo occupational safety environmental protection protection employee environment sustainable use natural resource promotion environmental awareness major component group mis sion statement prime importance boehringer ingelheim compliance social environmental aspect firmly anchor corporate philosophy year ensure achieve sustainability future generation groupwide long establish bind standard term environmental protection health safety work internal guideline reflect respective countryspecific require ment case far standard prescribe law particular follow international standard guidance document work close cooperation relevant association boehringer ingelheim corporate department environment health safety sustainability ehss responsible particular strategic focus group management report boehringer ingelheim continue characterised integration sanofis animal health division merial group addition safety environmental risk assessment new facility integration audits implement training platform ehs academy establish order provide employee ehss training develop awareness field technical support regular ehss audits boehringer ingelheim internal facility premise supplier contract manufacturer ensure compliance international standard company continuously review status environmental protection health safety work potential improvement identify basis close coordination stakeholder outside company extremely impor tant advance current topic relevant company take stand formu lating relate position paper order achieve continuous sustainable improvement world wide sake company topic range use improve refrigerant use certify natural resource careful handling plastic boehringer ingelheim support united nations sustainable development goal sdgs development correspond iso standard make contribution sustaina bility climate change conference katowice poland conference party cop ehss representatives boehringer ingelheim participate contribution reduce global greenhouse gas emission continue pursue goal activity futher reduce entire emission compare value achieve reduction goal futureoriented reduction environmental footprint overall interna tional green initiative step activity plan rollout safe safety initiative aim reduce number workplace accident continue successful workshop focus behaviourbased safety hold company worldwide facility high safety initiative define simple rule behaviour shall ensure improve occupational safety laicnanif detadilosnoc stnemetat boehringer ingelheim annual report employee report boehringer ingelheim employ people average worldwide represents increase previous year number staff increase region additional employee average number employee region americas europe asiaaustraliaafrica aaa major success factor positive growth group engage motivated staff accord ingly particularly commit actively develop support employee order well prepare challenge ahead comprehensive training system empha sise acquisition technical expertise promote social skill integration experience cultural background personality boehringer ingel heim create openness different approach opinion live corporate vision value innovation global company important diversity market reflect workforce create work environment embrace diversity difference pillar corporate culture boehringer ingelheim contribute factor company success addition competitive salary boehringer ingelheim offer benefit employee benefit include range company pension plan flexible homebase work option numer ous healthrelated benefit significant segment corporate strategy talent management department remit ensure employability staff promote wide range opportunity innovation work motivate employee nurture talent develop individual vocational training major importance boehringer ingelheim stand social responsibility company offer career opportunity great number young apprentice people time tie talented wellqualifie workforce young professional germany company backdrop demographic change young professional start career boehringer ingelheim germany different scientific technical com mercial field training dualstudy course december young people enrol vocational training programme germany company aim strengthen appeal boehringer ingelheim employer current future employee boehringer ingelheim recipient award effort area receive mark auditor international independent employer institute category salarie compensation benefit employee development performance management receive distinction facility germany facilities china taiwan brazil russia spain poland time singa pore number country organisation award rate unprecedented group management report evidence strong appeal development opportunity company employee potential recruit social responsibility take social responsibility important aspect corporate culture commitment wellbee patient employee family focus range project addition support people need initiative country region active company company activity focus protect maintain environment previous year boehringer ingelheim continue assist provide support integra tion people flee home country pursue broad range measure area boehringer ingelheim employee germany conduct workshop refugee addition company partnership deutsche universittsstiftung partnership boehringer ingelheim sponsor welcome scholarship programme support student crisis region company help candidate risis region area people flee join company offer apprenticeship opportunity complete introductory training year internship successfully complete internship employee offer permanent position past year major pillar social commitment make health mmh initiative start make health continuously develop social entrepreneurship movement com worldwide initiative pany externally socially entrepreneurial sustainable activity limit individual project relate region issue instead initiative focus creatively connect local international partner different sector network traditional visible invisible border central element successful social movement order identify pro mote implement innovative solution farreache complex challenge health care sector cocreation bridge social commercial entrepreneurship bring social entrepreneur nonprofit organisation health care sector boehringer ingel heim employee resource date mmh network boehringer ingelheim ashoka world large nonprofit organisation help social entrepreneur reach approximately million people worldwide area health care mmh initiative aim promote employee commitment social entrepreneurship order advance health care project different country work local external partner colleague boehringer ingelheim mmh leadership programme rural south ern india insight india participation online social intrapreneurship course opportunitie col laborate social entrepreneur mmh network executive residence internal competition promote employee project hone staff social entrepreneurial think ing activity strengthen network philosophy partnership nonprofit organisation social enterprise health care sector large number local pro ject take place employee actively involve improve health mean understand people environment everyday challenge offer solution need health awareness affordability accessibility health service acceptance play key role mmh play role university sector goal help student lecturer learn socially entrepreneurial think practical activity development health carerelate project laicnanif detadilosnoc stnemetat boehringer ingelheim annual report angel initiative european stroke organisation eso world stroke organisation wso stroke alliance europe safe national stroke association company boehringer ingelheim establish unique health initiative goal initi ative improve stroke care europe emerge market hospital angel initiative november initiative receive prestigious health collaboration award service delivery category european federation pharmaceu tical industry association efpia boehringer ingelheim establish introduce lastmile programme support global alliance livestock veterinary medicine galvme funding bill melinda gates foundation integrate solutionoriented initiative aim respond critical challenge field animal health ensure consistent availability medical resource animal hardtoaccess area subsaharan africa initiative currently focus ruminant sheep goat cattle expand include poultry project boehringer ingel heim help small farmer africa gain access veterinary medicine underline boehringer ingelheim strong social commitment aim positive impact human animal live area particularly vital need boehringer ingelheim value respect employee difference actively promote diverse cooperative open work environment conscious fact diversity mar ket customer reflect workforce diversity make right mix inclusion bring good result mix focus encourage inclusive environment kind diversity thrive boehringer ingelheim participate german diversity day motto fly flag diversity large german facility ingelheim biberach official member diversity charter early prout employer acknowledge prout work foundation group management report report economic position macroeconomic environment line worldwide economic growth rate slightly likewise register eurozone economic output grow strongly growth rate emerge market develop country level previous year slightly growth slowdown major economy reduction global growth expect year continuously expand emerge market develop country unable usa result increase private consumption investment intellectual property production well oil gas industry secondlong growth phase past year continue strongly expansionary fiscal policy form tax reform start stim ulated economic output time increase funding deficit tariff increase resolve usa start countertariff introduce affected trading partner response negative impact economic growth economic repercus sion relatively limited low proportion overall trade volume japan world thirdlarg economy record decline gross domestic product quarter year despite consistently low unemployment rate follow consecutive quarter growth economy manage grow year strongly attributable high rate utilisation exist capacity decrease growth export chinese economy continue undergo process structural transformation s vice sector assert comparison manufacturing sector chinese economys rate growth remain strong drive government high growth target weaken slightly compare previous year attributable restrictive market access condi tion foreign company china external trade political tension usa economic performance steadily increase asian region strong economic growth emerge market develop country particular global scale emerge market develop country provide ground concern argentina tur key relatively current account deficit significant debt level high inflation rate trigger devaluation country currency far limited country emerge market hold high foreign currency reserve term economic momentum eurozone record negative development attenuation foreign trade end exportdriven boom past year lack qualified personnel technical capacity result supplyside bottleneck manufacturing industry particular addition factor ongoing discussion introduction tariff certain product group eus postbrexit economic relationship united kingdom negatively affect sentiment eurozone hand unem ployment rate remain unchanged eurozone despite economic downturn inflation pick course year rise energy price wage cost laicnanif detadilosnoc stnemetat boehringer ingelheim annual report german economy continue grow past year trend weaken appreciably summer end year reason include production loss strike illness problem german automotive industry weak level demand eurozone world economys loss impetus present endure problem additional adverse effect foreign demand negatively affect economic condition inflation germany average close ecbs target level price increase strongly compare previous year aboveaverage increase price food luxury food item tobacco beer sharply increase price heat oil petrol global economic upturn expect weaken hand reflect fact advanced economy exhaust production capacity experience recruitment difficulty hand expect usas restrictive mon etary policy result significantly bad financing term latin america decelerate pace economic growth addition positive effect usas tax reform gradually recede background currency development effect net sale average rate basis eur eur million usd jpy cny gbp cad brl global pharmaceutical market register growth financial year iqvia global use medicine outlook trend drive rise demand industrialise country cancer medicine product treatment autoimmune disease antidiabetic medicine age population industrialise country industry growth remain stable surpassed growth previous year group management report earning position longterm sustainably successful development form basis secure company independence long term combine stable earning sound finance core boehringer ingelheim strategic focus previous year base approach principle boehringer ingelheim record net sale eur million financial year corre eur spond decrease compare previous year level eur million exchange rate development foreign exchange market associate exchange rate effect negative impact sale growth big market billion net sale currency adjust group growth rate stand leave aside discontinue operation interim contract agreement sign early follow exchange busi ness sanofi contribute significantly sale operating sale com pany core business area adjust currency effect grow sale eur million share overall sale america region remain boehringer ingelheim key sale market slight decline sale result negative currency effect north south america originary sale growth north america offset currencyadjuste basis sale america region increase compare previous year europe region register net sale eur million contribute group net sale correspond decline sale compare decrease largely consequence low previousyear sale discontinue operation currency effect significant impact asiaaustraliaafrica aaa region realise slight growth currencyadjuste basis net sale decline particularly japan net sales eur million achieve region corresponding share group total revenue net sales region eur million currency change adjust americas europe asiaaustraliaafrica aaa general sale growth conform expectation support good result clinical trial external partner able place promise new product market successfully push ahead wellestablishe product hand experience increasingly difficult market situation constantly challenge market access grow price pressure key market overall company assert despite difficult condi tion lay foundation future growth laicnanif detadilosnoc stnemetat boehringer ingelheim annual report material ratio take consideration change inventory improve result negative impact previous year sale merial company inventory assess market value addition relatively lowmargin service production agreement discontinue operation consumer health care business long include personnel expense increase increase number employee plus expense pension plan similar obligation depreciation amortisation increase mainly attributable writedown intangible asset animal health business impairment losse tangible asset france spain operating income include extraordinary effect total eur million eur million mainly restructure measure integration cost overall despite positive operating trend core business operating income line previous year level consider extraordinary effect meet expectation boehringer ingelheim record operating income eur million corresponding return sale percentage point previous year return sale key figure eur million change net sale operating income return net sale income taxis income taxis income taxis increase eur million mainly improved hold income financial result reflect increase interest expense pension commitment similar obli gation loss plan asset previous year include gain plan asset financial result improve tax expense negatively affect significant extraordinary effect result disposal consumer health care business tax reform usa negative factor long applicable report clearly positive income tax note regard provision german commercial law shareholder sonal taxis arise group business activity recognise tax expense instead taxis present withdrawal group equity take specificity account actual tax ratio markedly high figure show profit loss statement eur despite difficult market condition adverse currency effect boehringer ingelheim register positive development operating business financial year follow previous year shape integration process extraordinary tax effect conclude past year billion income income taxis eur million eur million taxis group management report development business past financial year boehringer ingelheim business activity divide area human pharmaceutical animal health biopharmaceutical net sale business eur million currency change adjust human pharmaceutical animal health biopharmaceutical sale discontinue operation human pharmaceutical total group revenue human pharmaceutical main pillar boehringer ingelheim business activity net sale business amount eur million equivalent change currency adjust compare previous year growth currency positive currencyadjuste sale growth result particular successful placement adjust human innovative product solid market position establish medicine pharmaceutical emerge market market key growth driver human pharma ceutical business hand significant market price pressure particularly establish medicine relatively strong euro represent difficult environment boehringer ingelheim nonetheless manage assert product spiriva treat chronic obstructive pulmonary disease copd big contributor sale generate revenue eur million reporting period previous year level eur million result increase price pressure boehringer ingelheim secondstrong product term sale anticoagulant pradaxa register sale eur million past year increase compare financial year type diabete medicine jardiance winner prix galien inter national innovative pharmaceutical product record strong growth achieve sale eur million jardiance reporting period correspond increase compare previous year eur million laicnanif detadilosnoc stnemetat boehringer ingelheim annual report net sale eur million change spiriva pradaxa jardiance trajenta jentadueto regard regional distribution sale human pharmaceutical business usa share far large market boehringer ingelheim generate sale eur million correspond increase compare previous year currencyadjuste secondbigg market eucan region europe canada australia new zealand account revenue eur million sale increase compare eur mil lion exchange rate effect significant influence sale trend japan sale decline eur million eur million partly expiry cooperation agreement product micardi net sale region eur million change usa europecanadaaustralianew zealand eucan emerge market japan strong sale increase growth market sale increase eur million currencyadjuste sale growth market previous year amount eur million china growth achieve compare result sale eur million group management report animal health sale product animal health business increase amount eur million currencyadjuste high net sale eur million change nexgard frontline ingelvac circoflex heartgard financial year report period antiparasitic vaccine ingelvac growth drive circoflex company good selling medicine antiparasitic product nexgard generate strong sale revenue eur million eur million record growth compare previous year follow antiparasitic frontline register decrease eur million eur million adverse currency effect product ingelvac circoflex vaccine porcine circovirus type achieve eur million sale financial year represent decline previous year eur million net sale region eur million change north america europe africaasiamiddle eastoceania metasia latin america biopharmaceutical financial year biopharmaceutical business maintain position industrial customer segment order situation entire business develop ositively result strong growth high capacity utilisation biopharmaceutical production sale increase eur million biopharmaceutical eur million laicnanif detadilosnoc stnemetat boehringer ingelheim annual report financial position eur million financial fund cash flow operating activity cash flow investing activity cash flow financing activity change financial fund cash relevant transaction change financial fund change consolidated company exchange rate movement financial fund boehringer ingelheim financial management instrument method aim secure liquid ity minimise financial risk optimise cost capital appropriate capital structure financial activity gear support business strategy cash flow operating activity amount eur million represent increase eur million comparison previous year eur million cash flow investing activity decline considerably eur million eur million prior year strongly affect cash settlement swap business sanofi tax payment result sale consumer health care business significant investment investment particular importance boehringer ingelheim strategic point view con tinuous investment requirement longterm development company form basis profitable growth business activity total eur million invest tangible intangible asset year review represent unchanged high level slight increase compare eur million furthermore eur million deposited plan asset pension similar obligation mainly usa toppingout ceremony autumn expansion production vienna austria strongly grow biopharmaceutical business represent big single investment tory boehringer ingelheim underway job create eur million invest facility significant site group decade important investment take place business human pharmaceutical despite dis posal chemical production site malgrat spain begin new proprietor future incorporate production network external strategic partner spain remain important site boehringer ingelheim group eur million invest project comprise production cartridge respimat product fill package global distribution sant cugat spain group management report important investment animal health business march groundbreake new production facility focus production avian vaccine begin lyon portedesalpe france expect offer employment people invest ment follow rise demand vaccine footandmouth disease result high poultry consumption cash outflow financing activity eur million mainly include payment shareholder interest pay overall take currency effect change group consolidate company consideration lead increase boehringer ingelheim group financial fund eur million eur million net asset position eur million change change asset intangible tangible asset financial asset fix asset inventory trade account receivable receivables current asset cash cash equivalent current asset asset total asset equity liability group equity provision pension similar obligation tax provision provision account payable loan great year liability liabilitie difference capital consolidation total equity liability laicnanif detadilosnoc stnemetat boehringer ingelheim annual report financial year boehringer ingelheim total asset amount eur million increase eur million compare previous year significant reason development financial fund rise eur million result positive cash flow increase defer tax asset work capital trade receivables inventory fix asset contribute rise despite depreciation amortisation impairment high investment activity initial consolida tion viratherapeutic gmbh positive currency effect lead slight increase tangible intangible asset financial asset go reversal impairment loss previous year inventory trade receivable grow significantly eur million result high working capital usa emerge market especially china japan receivable current asset decrease mainly low tax prepayment usa france ger increase asset arise higher defer tax asset base temporary differ ence fix asset high plan asset pension similar obligation usa increase equity ratio increase group equity eur million result group profit spite high positive currency effect surpass withdrawal shareholder group equity balance sheet total december amount eur million equity ratio improve december addition equity pension provision longterm liability group disposability long term total item amount eur mil lion represent share total asset consequently longterm disposable capital cover intangible tangible asset work capital pension provision increase high actuarial interest rate utilisation update mortality table provision discount guarantee usa tax provision germany go comparison previous reporting year trade account payable liability bank slightly decrease liability increase high tax liability germany liability decline mainly reversal difference capital consolidation low defer tax liability temporary difference fix asset boehringer ingelheim positive development financial year reflect net asset position boehringer ingelheim remain soundly finance profitable company group management report report opportunitie risk opportunitie risk management assess risk context holistic opportunity risk management endeav account result opportunity opportunity management base strat egie objective company individual business operate business unit integral groupwide planning management system responsible busi ness function bear direct responsibility early systematic identification analysis use opportunity boehringer ingelheim researchdriven innovative pharmaceutical company current activity consider relevant opportunity relevant project illustrate research development chapter aim risk management system implement boehringer ingelheim identify busi nessspecific risk particular risk jeopardise continued existence company early possible assess reduce reasonable level mean suitable measure person responsible key business function include process calculate assess risk groupwide risk information system ensure identify risk analyse assess carefully follow appropriate classification catego rie adequate risk management measure initiate implementation consistently monitor year review internal auditing perform target routine audit extraordinary audits world addition adherence legal requirement internal group guideline main focal point functionality system effectiveness internal control prevention loss asset efficiency structure process correspond adjust ment optimisation initiate necessary individual risk important risk boehringer ingelheim expose broken follow e specific category financial risk legal risk production environmental risk personnel risk industryspecific risk risk identify concrete appear controllable mean specific management procedure term abstract case risk completely control mean target management procedure regardless probability occurrence financial risk relevant financial risk break follow currency risk credit country specific risk financial investment shareholding risk laicnanif detadilosnoc stnemetat boehringer ingelheim annual report currency risk global orientation business activity subject opportunity risk exchange rate volatility particularly regard dollar japanese yen group monitor quantifie risk regular interval make predictable future business mean rel evant hedging strategy appropriate financial instrument forward exchange contract resultant risk subsequently designate concrete controllable limited credit countryspecific risk boehringer ingelheim expose credit countryspecific risk result interna tional business activity portfolio trade account receivable trade account payable identify extraordinary risk group usual level sector apply possible default risk receivables largely hedge economic political risk continue carefully track credit countryspecific risk position respond negative change timely manner risk consider moderate fore regard concrete financial investment shareholding risk group pursue defensive investment strategy management financial asset reflect orientation portfolio focus european economic monetary union emu government bond credit rating shortterm investment select bank result concrete controllable limited risk limit opportunity major financial investment net book value strategic investment relate company affect market business circumstance lead high vola tility fair market value specific risk cover respective impairment con solidated financial statement legal risk business activity group expose legal risk distinction regula tory liability patent protection risk regulatory risk boehringer ingelheim expose risk arise legal dispute proceeding official investigation legal administrative decision ongoing future proceeding predict regard resultant risk abstract high liability risk marketing sale pharmaceutical expose potential product liability risk boehringer ingelheim currently product liability insurance company risk profile absolutely guarantee insurance coverage maintain reasonable cost accept able condition sufficient protect boehringer ingelheim claim loss potential claim loss case foreseeable product liability insurance cover partially cover specific liability risk remain risk exposure cover pro vision moderate risk group group management report furthermore product liability claim tie substantial financial resource management capacity detrimental company image event market consider product unsafe ineffective result unexpected effect moderate abstract risk patent protection risk protection innovation trademark brand patent right particular importance boehringer ingelheim research company commercial protective right increasingly target attack breach take necessary precaution allow detect threat early stage commence appropriate countermeasure defend legal position legal mean available moderate risk regard concrete production environmental risk quality management system compliance process continuously optimise close coop eration relevant authority order ensure compliance cgmp standard current good manufacturing practice risk area continue high significance group classify abstract order guarantee supply product market implement measure guarantee reliable highquality supply internal external customer addition supplier management procurement involve build internal standby capacity result risk concrete risk area environment health safety sustainability ehss preemptively mini mised ensure global adherence high safety standard appropriate emergency plan draw possible incident kind practise subject comprehensive quality testing regular interval result measure risk class concrete limited personnel risk boehringer ingelheim company expose demographic change resultant risk affect lack appropriately qualified personnel potential risk substantial impact company business activity include longterm planning process year gain strategic significance result boehringer ingelheim counter risk mean comprehensive personnel concept con text global personnel management present group opportunity regardless ethnic background gender religion offer company employee development opportuni tie base vocational skill social expertise personal aptitude willingness responsibility accordance need company view countermeasure describe risk regard moderate concrete industryspecific risk boehringer ingelheim expose business risk specific pharmaceutical industry risk materialise past financial year increase significance result impact boehringer ingelheim continue class significant abstract laicnanif detadilosnoc stnemetat boehringer ingelheim annual report addition loss exclusivity product establish market risk associate development registration new product industryspecific risk increasingly include change restrictive requirement relate pricing reimbursement sale market frequently price pharmaceutical product subject state monitoring regula tion price pressure cheap generic drug cause state reimbursement sys tem boehringer ingelheim keep close eye change sale market take appropriate measure response current development overall statement risk situation current perspective aware risk conjunction risk lead lasting impairment company net asset financial earning position jeopardise continued existence boehringer ingelheim report expect development boehringer ingelheim look successful financial year achieve ambitious target absolute figure comparison competitor lay foundation sustainable development longterm growth demonstrate consistent focus business innovationoriente field strategic exchange sanofis animal health business merial boehringer ingelheim consumer health care business transaction successfully close january transaction improve competitiveness animal health business industry important growth mar ket animal health business grow second year follow integration merial busi ness successfully manage demand task incorporate organisation product new customer process expect provide group growth momentum future sale growth increasingly difficult market environment increase unpredictability business pose expect major challenge entire pharmaceutical industry continue require significant atten tion boehringer ingelheim regard competitiveness impor tant retain scope growth innovation financial ability act continue successful market future view change pro cesse healthcare system face ageing population increase price pressure major market expect low growth impetus pharmaceutical industry come year comparable basis adjust currency extraordinary effect expect slight increase net sale boehringer ingelheim expense remain continuously high line strategy drive growth promote new product future primarily product facility invest area care close investigation therapeutic benefit associate prospect success replenishment innovative medicine research pipeline show short mid longterm growth potential envisage slight increase investment new phar maceutical group management report addition patent expiry attack patent major challenge face researchdriven pharmaceutical industry increase investment big hurdle increase cost associate product approval context increase cost pressure healthcare system outline particularly emphasise system increa ingly unwilling substantially adequately reward high investment development new medicine value contribution increase efficiency system result significant price pressure major market prescription medicine conjunction long plan development cycle new product make business predictable require recognise seize opportunity quickly hand subject cost strategy continual monitoring adjustment hand end launch initiative past year accelerate reaction change reduce organisational complexity low cost base order create potential investment secure company longterm success difficult market environment hand potential result measure introduce promise new product launch hand plan operating income comparable basis adjust currency extraordinary effect slightly year level familyowne company boehringer ingelheim primary aim maintain group indepen boehringer ingelheim dence competitiveness longterm sustainable organic growth take precedence position shortterm profit target confident achieve ambitious target future business thank great innovative strength base comprehensive portfolio prospective product global presence support highly qualified motivated employee stand vision value innovation develop bring market innovative prod uct area high unmet medical need therapeutic approach aim aim endeavour new medicine available allow treatment human animal effectively currently possible laicnanif detadilosnoc stnemetatspage overview select consolidated company consolidate balance sheet consolidated profit loss statement cash flow statement statement change group equity note consolidate financial statement independent auditor report laicnanif detadilosnoc stnemetat boehringer ingelheim annual report overview select consolidated company boehringer sohn ingelheim rhein boehringer ingelheim vetmedica gmbh ingelheim rhein argentina mexico germany boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim corporate argentina buenos air mxico mexico city center gmbh ingelheim rhein australia netherlands boehringer ingelheim gmbh ingelheim rhein boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim pharma australia pty ltd netherlands alkmaar gmbh ingelheim rhein north ryde boehringer ingelheim micropart new zealand gmbh dortmund belgium boehringer ingelheim animal health boehringer ingelheim venture fund boehringer ingelheim animal health new zealand ltd manukau city gmbh ingelheim rhein belgium brussels boehringer ingelheim puerto rico biopharmaceutical gmbh brazil ingelheim rhein boehringer ingelheim animal health boehringer ingelheim animal health puerto rico llc boehringer ingelheim veterinary brasil ltda paulo barceloneta research center gmbh hanover canada south africa boehringer ingelheim middle east africa gmbh ingelheim rhein merial canada inc burlington boehringer ingelheim animal health south africa pty ltd randburg china south korea nanchang boehringer ingelheim animal health ltd nanchang boehringer ingelheim animal health boehringer ingelheim animal health korea ltd seoul shanghai ltd shanghai spain denmark boehringer ingelheim animal health boehringer ingelheim animal health espaa barcelona denmark copenhagen taiwan france boehringer ingelheim animal health merial sas lyon taiwan ltd taipei great britain thailand boehringer ingelheim animal health boehringer ingelheim animal health limit bracknell thailand limited bangkok italy usa boehringer ingelheim animal health boehringer ingelheim animal health italia spa milan usa inc wilmington delaware japan boehringer ingelheim animal health japan ltd tokyo distribution production research development consolidate financial statement overview select consolidated company boehringer sohn grundstcksverwaltung gmbh ingelheim rhein boehringer ingelheim international gmbh ingelheim rhein argentina colombia italy south africa boehringer ingelheim boehringer ingelheim boehringer ingelheim italia spa ingelheim pharmaceutical buenos aire santa bogot milan proprietary ltd randburg bidachem spa fornovo giovanni australia czech republic south korea boehringer ingelheim pty ltd boehringer ingelheim spol sro japan boehringer ingelheim korea ltd north ryde prague nippon boehringer ingelheim ltd seoul tokyo boehringer ingelheim vetmedica austria denmark boehringer ingelheim seiyaku korea ltd seoul yamagata boehringer ingelheim rcv gmbh boehringer ingelheim danmark vienna copenhagen boehringer ingelheim japan inc spain tokyo forschungsinstitut molekulare boehringer ingelheim espaa pathologie gesellschaft mbh vienna ecuador barcelona mexico boehringer ingelheim del ecuador belgium cia ltda quito boehringer ingelheim mexico sweden mexico city scs boehringer ingelheim commv boehringer ingelheim aktiebolag brussels finland boehringer ingelheim vetmedica stockholm guadalajara boehringer ingelheim finland brazil espoo switzerland netherlands boehringer ingelheim brasl boehringer ingelheim schweiz qumica farmaceutica ltda france boehringer ingelheim alkmaar gmbh basel paulo boehringer ingelheim france sas solana agro pecuria ltda arapongas paris new zealand taiwan boehringer ingelheim ltd boehringer ingelheim taiwan ltd canada great britain auckland taipei boehringer ingelheim canada ltd boehringer ingelheim ltd toronto bracknell norway thailand boehringer ingelheim norway boehringer ingelheim thai limited chile greece asker bangkok boehringer ingelheim ltda boehringer ingelheim ella santiago chile athens philippines turkey boehringer ingelheim philippines boehringer ingelheim ila ticaret china hong kong inc manila istanbul boehringer ingelheim shanghai boehringer ingelheim hong kong pharmaceuticals ltd shanghai ltd hong kong poland usa boehringer ingelheim boehringer ingelheim boehringer ingelheim biopharmaceutical china ltd india warsaw pharmaceuticals inc shanghai wilmington delaware ino mng dim china lto mrin igelheim india private portugal boehringer ingelheim fremont inc wilmington delaware shanghai unilfarmauniao internacional boehringer ingelheim international indonesia laboratrios farmacuticos lda boehringer ingelheim usa trading shanghai ltd lisbon corporation wilmington delaware boehringer ingelheim indonesia shanghai boehringer ingelheim vetmedica jakarta russian federation vietnam china ltd taizhou israel ooo boehringer ingelheim moscow boehringer ingelheim animal health vietnam limited liability company boehringer ingelheim israel ltd chi minh city tel aviv oiloftrop tcudorp boehringer ingelheim annual report consolidate balance sheet asset eur million note intangible asset tangible asset financial asset fix asset inventory account receivable asset cash cash equivalent current asset prepaid expense defer tax asset exceed plan asset total asset equity liability eur million note shareholder capital group reserve balance sheet currency conversion difference equity attributable parent company noncontrolle interest group equity difference capital consolidation provision account payable loan liability defer income defer tax liability total equity liability explanation relevant section note consolidated financial statement consolidate financial statement consolidate balance sheet consolidate profit loss statement consolidated profit loss statement eur million note net sale change finish good work process work capitalise operating income total revenue cost material personnel expense amortisation intangible asset depreciation tangible asset operating expense operate income financial income hold income income taxis income taxis income taxis net incomeloss noncontrolle interest group profitloss explanation relevant section note consolidated financial statement legal requirement shareholder personal taxis arise group business activity show withdrawal group reserve oiloftrop tcudorp boehringer ingelheim annual report cash flow statement eur million income taxis include noncontrolle interest amortisation reversal writedown intangible asset depreciation reversal writedown tangible asset change provision pension similar obligation acquire generate plan asset change provision noncash income expense gain disposal consolidated company gainloss disposal fix asset grant receive change inventory change account receivable asset relate investing financing activity change trade account payable liability relate investing financing activity interest incomeinterest expense income investment incomeexpense extraordinary magnitude significance income taxis income taxis pay cash flow operating activity payment acquire intangible fix asset payment acquire tangible fix asset payment acquire financial fix asset payment acquire generate plan asset investment consolidated company proceed disposal intangible fix asset proceed disposal tangible fix asset proceed disposal financial fix asset cash receipt relate purchase price adjustment consolidated company cash receipt extraordinary magnitude significance interest receive income dividend cash flow investing activity consolidate financial statement cash flow statement statement change group equity cash flow statement eur million cash receipt grant interest pay cash payment shareholder parent company cash payment shareholder parent company proceed loan cash repayment loan cash flow financing activity change financial fund cash relevant transaction change financial fund change consolidated company change financial fund exchange rate movement financial fund financial fund excl investment security cash cash equivalent investment security fix asset source fund use fund statement change group equity balance sheet equity attri currency butable non shareholders group conversion parent control eur million capital reserve difference company interest group equity balance withdrawal net loss change consolidate company currency effect balance contribution withdrawal net income change consolidate company currency effect balance shareholder capital consist equity boehringer sohn boehringer sohn grundstcksverwaltung gmbh shareholders capital consist limited partner capital contribution shareholder personal taxis arise group business activity show withdrawal group reserve oiloftrop tcudorp boehringer ingelheim annual report note consolidated financial statement principle method general principle consolidate financial statement boehringer ingelheim financial year prepare accord ance section german commercial code hgb line legal requirement prepare consolidated financial statement section seq hgb accordance section hgb consolidated financial statement consist consolidated balance sheet consolidated profit loss statement note consolidated financial statement cash flow statement statement change equity consolidated financial statement prepare euro accordance section conjunction section hgb improve clarity transparency consolidated financial statement individual item consoli date balance sheet consolidated profit loss statement combine item present explain separately note additional disclosure require individual item find note registry information parent company register boehringer sohn headquarters ingelheim rhein commercial register mainz district court number hra information group consolidated companies parent company boehringer ingelheim group boehringer sohn ingelheim rhein boehringer ingelheim rhein sole personally liable manage shareholder company boehringer sohn boehringer sohn grundstcksverwaltung gmbh ingelheim rhein general partner control boehringer sohn boehringer ingelheim group consist total affiliated company germany abroad consol idate financial statement boehringer sohn include fully consolidate subsidiary boehringer sohn grundstcksverwaltung gmbh consolidated special purpose entity majority risk reward business activity attributable boehringer sohn remain subsidiary boehringer sohn directly indirectly hold majority voting right accordance section hgb affiliate company include consolidation reporting year individually collectively insignificant group net asset financial earning position total sale equity net income year affiliate company include consolidation account aggregated group financial statement total affiliate company ongoing restriction control term article association company consolidate accordance section hgb consolidated financial statement note total number affiliate company decrease compare previous year new company found company acquire company lose separate legal identity merger affiliate company liquidate viratherapeutic gmbh innsbruck acquire september follow subsidiary exempt duty prepare disclose annual financial statement management report accordance section hgb boehringer ingelheim gmbh ingelheim rhein boehringer ingelheim europe gmbh ingelheim rhein boehringer ingelheim secura versicherungsvermittlung gmbh ingelheim rhein boehringer ingelheim grundstcksgesellschaft mbh ingelheim rhein boehringer ingelheim finanzierung gmbh ingelheim rhein boehringer ingelheim beteiligung gmbh ingelheim rhein boehringer ingelheim venture fund gmbh ingelheim rhein boehringer ingelheim invest gmbh ingelheim rhein follow subsidiary exempt duty prepare disclose annual financial statement management report accordance section hgb boehringer sohn ingelheim rhein boehringer sohn grundstcksverwaltung gmbh ingelheim rhein boehringer ingelheim pharma gmbh ingelheim rhein boehringer ingelheim veterinary research center gmbh hanover joint venture include cost instead proportionate method equity method lack significance accordance section hgb associate company valuate equity method lack significance oiloftrop tcudorp boehringer ingelheim annual report consolidation method inventory fix asset receivables liability income expense item transaction company include consolidation eliminate debt consolidation procedure accordance section hgb procedure eliminate intercompany profit accordance section hgb income expense consolidation procedure accordance section hgb acquisition method apply include subsidiary consolidation time accordance section hgb company include consolidation time date company subsidiary book value share hold parent company offset correspond equity subsid iary equity carry fair value asset liability prepay expense defer income special reserve include consolidated financial statement time consolidation remain positive balance record goodwill remain negative balance record difference capital consolidation currency translation asset liability result foreign currency transaction translate average spot exchange rate balance sheet date realisation principle section conjunction section halfsentence hgb historical cost convention section conjunction section sentence hgb apply item remain term year consolidated financial statement financial statement foreign subsidiary domicile state outside eurozone denominate foreign currency convert euro accordance section hgb modify closing date rate method modify closing date rate method asset liability item annual financial statement pre pare foreign currency translate euro average spot exchange rate balance sheet date exception equity translate historical rate item include profit loss statement translate euro average rate result translation difference report consolidated equity reserve balance sheet currency conversion difference exchange rate group important currency change follow report year basis eur closing rate average annual rate dollar japanese yen chinese renminbi pound sterling consolidated financial statement note accounting policy fix asset acquire intangible asset tangible fix asset carry cost schedule straightline amortisation depreciation consider technical economic circumstance base follow useful life intangible asset year building year technical equipment machinery year equipment operate office equipment year straightline depreciation amortisation consolidated financial statement additional writedown record reflect impairment value asset consider permanently impaired manufacturing cost include material labour manufacturing cost appropriate portion mate rial labour overhead depreciation fix asset extent cause production manufacturing cost include financing cost capitalise intangible asset finite useful life useful life year apply goodwill viratherapeutic gmbh acquire year past experi ence product sale market business condition viratherapeutic gmbh indicate present true fair view financial asset primarily include investment security shareholder right loan carry low cost fair market value impair reason impairment previous financial year long exist appropriate writeup current asset prepay expense defer charge exceed plan asset inventory carry low cost fair market value raw material consumable supply capitalise low average acquisition price fair market value balance sheet date finish good work progress measure manufacturing cost basis individual calculation take account directly attributable cost material direct labour cost special direct cost appropriate portion material production overhead cost productionrelate depreciation good resale value lower acquisition cost fair market value oiloftrop tcudorp boehringer ingelheim annual report identifiable risk inventory arise aboveaverage storage period diminish marketability low replacement cost take account record appropriate valuation adjustment inventory value lossfree deduction expect sale price reflect cost incur receivables asset recognise cost allowance specific risk general credit risk lowinter noninterestbeare receivables term year discount cash cash equivalent consist cash balance bank cheque recognise low cost fair market value prepay expense record accordance section hgb include expense pay advance respect define period time balance sheet date defer income record accordance section hgb include proceed represent income relate define period time balance sheet date fair market value plan asset correspond present value pension obligation offset accord german gaap exceeding plan asset capitalise separately difference capital consolidation difference capital consolidation report december primarily result business swap boehringer ingelheim consumer health care business sanofis animal health business complete january result difference capital consolidation eur million difference amortise estimate period year remain balance difference amount eur million december difference capital consolidation report december include arise acquisition company original difference amount eur million difference amor tise estimate period year remain balance difference amount eur million december income release difference arise capital consolidation include operate income release correspond amortisation asset acquire company identify purchase price allocation previously recognise company balance sheet consolidate financial statement note group reserve group reserve include retain earning consolidate subsidiary prior current year consolidation entry affect earning provision tax provision provision include uncertain liability expect loss executory contract carry require settle obligation base reasonable prudent commercial judgement include future cost price increase provision remain maturity year discount matchedterm average market interest rate case pension provision interest rate result year average case provision seven year average accordance rckstellungsabzinsungsverordnung german regulation discount provision account payable loan account payable loan recognise settlement defer taxis calculate defer taxis arise temporary quasipermanent difference carry amount asset liability prepay expense defer income group financial statement carry amount tax purpose tax loss carryforward amount result tax benefit expense time difference reverse measure tax rate specific respective consolidated company defer tax balance discount difference consolidation measure accordance section hgb measure company specific tax rate applicable time expect reversal difference defer tax asset loss carryforward take account likely year defer tax asset liability report offset oiloftrop tcudorp boehringer ingelheim annual report note consolidated balance sheet intangible asset acquire concession advance eur million similar right goodwill payment total acquisitionmanufacturing cost balance january currency conversion difference change consolidate company addition disposal reclassification balance december currency conversion difference change consolidate company addition disposal reclassification balance december accumulate amortisation balance january currency conversion difference change consolidate company addition writeup disposal reclassifications balance december currency conversion difference change consolidate company addition writeup disposal reclassification balance december book value december book value december consolidated financial statement note tangible asset advance technical facility payment land facility operating construction eur million building machine equipment progress total acquisitionmanufacturing cost balance january currency conversion difference change consolidate company addition disposal reclassification balance december currency conversion difference change consolidate company addition disposal reclassification balance december accumulate depreciation balance january currency conversion difference change consolidate company addition writeup disposal reclassifications balance december currency conversion difference change consolidate company addition writeup disposal reclassification balance december book value december book value december oiloftrop tcudorp boehringer ingelheim annual report financial asset investment loan investment affiliate affiliate relate advance investment eur million company company company payment security loan total acquisitionmanufacturing cost balance january currency conversion difference change consolidate company addition disposal reclassification balance december currency conversion difference change consolidate company addition disposal reclassification balance december accumulate amortisation balance january currency conversion difference change consolidate company addition writeup disposal reclassifications balance december currency conversion difference change consolidate company addition writeup disposal reclassification balance december book value december book value december previous year loan item include loan shareholder consolidated financial statement note inventory eur million raw material supply unfinished good finish good good resale advance payment supplier account receivable asset residual term residual term eur million year year trade account receivable receivables affiliate company receivables related company asset asset item include receivables shareholder half million euro previous year eur million receivable affiliate company exclusively consist receivables loan receivables related company primarily consist trade account receivable provision eur million pension provision similar obligation tax provision provision oiloftrop tcudorp boehringer ingelheim annual report provision pension similar obligation provision pension similar obligation determine basis actuarial calculation project unit credit method take account future adjustment salarie pension addition local biometric datum germany mortality table publish prof klaus heubeck adjust groupspecific death probability invalidity rate pension obligation significant country calculate basis follow actuarial parameter december germany usa japan discount rate salary increase pension increase discount rate determine reference average market rate year maturity accordance german regulation discount provision march interest rate discount significant foreign pension obligation usa japan determine comparable parameter line german regulation discount provision march difference calculate accordance section hgb amount eur million plan asset intend solely cover pension similar obligation unavailable creditor plan asset define section sentence hgb measure fair market value essentially derive stock market price offset underlie pension similar obligation fair market value plan asset balance sheet date eur million relate pension obligation similar obligation eur million gain loss plan asset interest expense relate pension similar obligation offset accordance section sentence hgb total eur mil lion loss plan asset eur million interest expense relate pension similar obligation include interest expense relate pension similar obligation provision financial result tax provision tax provision include provision double taxation risk result follow implementation action plan organisation economic cooperation development oecd international initiative know action plan base erosion profit shift bep consolidated financial statement note provision provision mainly include provision discount guarantee personnelrelate provision provision outstanding invoice provision litigation legal claim compensation damage account payable loan residual term residual term greater great eur million year year year year bank loan account payable trade account payable advance payment receive account payable affiliate company account payable relate company liabilitie taxis eur million social security liability eur million previous year liability secure mortgage similar collateral right balance sheet date end year liability shareholder eur million previous year eur million present liability item account payable affiliate company include loan amount eur million previous year eur million trade account payable amount eur million previous year eur million oiloftrop tcudorp boehringer ingelheim annual report note consolidated profit loss statement structure consolidated profit loss statement base total cost format taxis include operating expense net sale business eur million human pharmaceutical animal health biopharmaceutical sale dicontinue operation geographic region eur million europe germany americas usa asiaaustraliaafrica japan operating income operating income include income currency translation eur million previous year eur million cost material eur million cost raw material supply good resale expenditure service consolidate financial statement note personnel expense eur million wage salarie social benefit retirement benefits retirement benefit interest effect measurement provision pension similar obligation show separate item financial income average headcount production administration marketing sale research development apprentice allocation employee different function restate merial employee allocate respective function year merial consolidate report administration amortisation intangible asset depreciation tangible asset amortisation intangible asset depreciation tangible fix asset include extraordinary writedown eur million previous year eur million operating expense operating expense include expense currency translation eur million previous year eur million addition item include operating expense mainly charge record provision legal risk restructure thirdparty service research development medicine marketing purpose administrative expense fee contribution commission rent freight expense repair carry party oiloftrop tcudorp boehringer ingelheim annual report financial income eur million interest expense relate pension similar obligation provision interest expense similar expenditure interest expense similar expenditure amortisation loss disposal financial fix asset shortterm invest ment income investment security longterm loan interest income similar income hold income eur million writedown financial fix asset writeup financial fix asset income relate company disposal related company income taxis eur million current income taxis defer taxis current income taxis primarily include corporation trade tax expense consolidated company total balance defer tax asset balance sheet date amount eur million previous year eur million defer tax asset primarily arise difference book value provision pension obligation discount tax goodwill intangible fix asset inventory tangible fix asset defer tax liability eur million previous year eur million record primarily relate difference book value intangible fix asset tangible fix asset inventory provision consolidated financial statement note net income net income positively influence priorperiod operating income mainly reversal provision tax refund prior year eur million previous year eur million negatively influence priorperiod operating expense mainly additional payment taxis prior year eur million previous year eur million note cash flow statement cash flow statement show change cash cash equivalent cash longterm investment security sell time boehringer ingelheim group result cash inflow outflow report year accordance german accounting standard cash flow statement dr cash flow statement break accord cash flow operating activity cash flow invest financing activity change balance sheet item affiliate company include translate average rate year balance sheet cash cash equivalent carry closing rate effect exchange rate change cash cash equivalent show separately financial fund include financial asset remain maturity exceed month date acquisition convert cash short term financial fund december comprise follow item eur million cash cash equivalent financial asset financial fund include eur million restrict fund balance sheet date oiloftrop tcudorp boehringer ingelheim annual report disclosure contingent liabilitie eur million liability guarantee warranty grant security thirdparty liability risk utilisation contingent liability assess low account good net asset financial earning position financial commitment offbalance sheet transaction eur million rental lease obligation residual financial commitment pensionrelate rental lease obligation eur million previous year eur million eur million previous year eur million relate longterm rental obligation nonconsolidate affiliated company purpose lease agreement low capital commitment compare acquire property absence resale risk risk arise term lease possible continue utilise property fully indication time residual financial commitment include future expenditureeffective investment eur million previous year eur million derivative financial instrument valuation unit extensive international structure boehringer ingelheim group highly dependent development world currency interest rate hedge risk particularly emerge good service finance currency forwards option generally currency risk interest rate swap option interest rate risk use derivative financial instrument organisational process set internal guideline strict separation trading processing documentation control consolidated financial statement note risk position regularly track analysed measure special groupwide financial report position enter periodically reevaluate monitor fair value derivative financial instrument cal culate generally accept market valuation method currency forward base present value method take account market datum balance sheet date provision eur million recognise currency forward include hedge accounting negative fair value currency balance sheet date line imparity principle positive fair value currency recognise balance sheet date derivative financial instrument include hedge accounting valuation unit follow nominal value fair value eur million foreign exchange forward contract extent requirement hedge account foreign currency forward exchange contract highly probable forecast transaction accordance section hgb meet foreign currency forward exchange contract recognise balance sheet line net hedge presentation method follow accounting policy apply recognition valuation group accordance section hgb economic hedge account financial statement use valuation unit valuation unit recognise foreign currency base net highly probable forecast transaction cur rency forwards match forecast net cash flow term maturity nominal foreign currency macro hedge highly probable forecast transaction income outgoing payment plan sale purchase derive company plan expost analysis planning show plan transac tion highly probable oppose change value hedge item hedge instrument fully offset critical term maturity nominal foreign currency match effective hedge assume prospectively retrospectively critical term match method exclusively measure prospective retrospective effectiveness hedge excess amount hedging transaction include valuation unit oiloftrop tcudorp boehringer ingelheim annual report december hedge highly probable forecast net cash flow recognise follow january december net cash flow eur million foreign exchange forward contract eur million nominal value nominal value fair value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn cad cad cad gbp gbp gbp january december net cash flow eur million foreign exchange forward contract eur million nominal value nominal value fair value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn cad cad cad gbp gbp gbp january december net cash flow eur million foreign exchange forward contract eur million nominal value nominal value fair value usd usd usd jpy jpy jpy consolidated financial statement note january february net cash flow eur million foreign exchange forward contract eur million nominal value nominal value fair value usd usd usd jpy jpy jpy year hedge accounting valuation unit long short position derivative offset nominal value eur million japanese yen furthermore december valuation unit foreign currency receivable recognise follow receivables eur million foreign exchange forward contract eur million nominal value nominal value fair value rub rub rub pln pln pln hedge foreign currency risk correlate relative change exchange rate planning date realisation date forecast transaction currency appreciate depreciate euro foreign currency risk plus minus eur million hedge research development expense eur million research development expense noncapitalise research development expense include item cost associate clinical study shareholding list company include consolidated financial statement list shareholding present accordance section hgb include audit consolidated financial statement submit german federal gazette subsequent event end financial year aware event material significance group lead reappraisal net asset financial earning position oiloftrop tcudorp boehringer ingelheim annual report total auditor fee total fee charge group auditor financial year amount eur million eur million relate audits financial statement eur million tax advisory service eur million service ingelheim rhein march boehringer board manage director hubertus von baumbach joachim hasenmai allan hillgrove andreas neumann michel pairet michael schmelmer independent auditor report independent auditor report boehringer sohn ingelheim rhein qualified audit opinion consolidated financial statement audit opinion group manage ment report audit consolidated financial statement boehringer sohn ingelheim rhein subsidiary group comprise consolidated balance sheet december consolidated profit loss statement cash flow statement statement change group equity financial year january december note consolidated financial statement include summary significant accounting policy addition audit group management report boehringer sohn financial year january december opinion basis knowledge obtain audit effect matter describe section basis qualified audit opinion consoli date financial statement audit opinion group management report accompany consol idate financial statement comply material respect requirement german commercial law true fair view asset liability financial position group december financial performance financial year january december accordance german legally require accounting principle accompany group management report provide appropriate view group position material respect group management report consistent consolidated financial statement complie german legal requirement appropriately present opportunity risk future development pursuant section sentence hgb handelsgesetzbuch german commercial code declare qualification audit opinion consolidated financial statement mention audit lead reservation relate legal compliance consolidated financial statement group management report basis qualified opinion consolidated financial statement audit opinion group management report contrary section number letter hgb total remuneration grant member member board manage director pension provision recognize recognize member board manage director disclose note consol idate financial statement conduct audit consolidated financial statement group management report accord ance section hgb german generally accept standard financial statement audits promul gate institut der wirtschaftsprfer institute public auditor germany idw responsibility requirement principle describe auditor responsibility audit consolidated financial statement group management report section auditor report independent group entity accordance requirement german commercial professional law oiloftrop tcudorp boehringer ingelheim annual report fulfil german professional responsibility accordance requirement believe evidence obtain sufficient appropriate provide basis opinion consolidate financial statement group management report information management responsible information information comprise annual report exception audit consolidated financial statement group management report auditor report opinion consolidate financial statement group management report cover information consequently express opinion form assurance conclusion thereon connection audit responsibility read information consider information materially inconsistent consolidated financial statement group management report knowledge obtain audit appears materially misstate responsibility management consolidated financial statement group management report management responsible preparation consolidate financial statement comply material respect requirement german commercial law consolidated financial statement true fair view asset liability financial position financial performance group compliance german legally require accounting principle addition management responsible internal control accordance german legally require accounting principle determine necessary enable preparation consolidated financial statement free material misstatement fraud error prepare consolidated financial statement management responsible assess group ability continue go concern responsibility disclose applicable matter relate go concern addition responsible financial reporting base go concern basis accounting provide actual legal circumstance conflict therewith furthermore management responsible preparation group management report provide appropriate view group position material respect consistent consoli date financial statement complie german legal requirement appropriately present opportunity risk future development addition management responsible arrangement measure system consider necessary enable preparation group management report accordance applicable german legal requirement able provide sufficient appropriate evidence assertion group management report independent auditor report auditor responsibility audit consolidated financial statement group manage ment report objective obtain reasonable assurance consolidated financial statement free material misstatement fraud error group management report provide appropriate view group position material respect consistent consolidated financial statement knowledge obtain audit complie german legal require ment appropriately present opportunity risk future development issue auditor report include opinion consolidate financial statement group management report reasonable assurance high level assurance guarantee audit conduct accordance section hgb compliance german generally accept standard financial statement audits promulgate institut der wirtschaftsprfer idw detect material misstatement misstatement arise fraud error consider material individually aggregate reasonably expect influence economic decision user take basis consoli date financial statement group management report exercise professional judgement maintain professional scepticism audit identify assess risk material misstatement consolidated financial statement group management report fraud error design perform audit procedure responsive risk obtain audit evidence sufficient appropriate provide basis opinion risk detect material misstatement result fraud high result error fraud involve collusion forgery intentional omission misrepresentation override internal control obtain understand internal control relevant audit consolidate financial statement arrangement measure system relevant audit group management report order design audit procedure appropriate circumstance purpose express opinion effectiveness system evaluate appropriateness accounting policy management reasonableness estimate management relate disclosure conclude appropriateness management use go concern basis accounting base audit evidence obtain material uncertainty exist relate event condition cast significant doubt group ability continue go concern conclude material uncertainty exist require draw attention auditor report relate disclosure consolidate financial statement group management report disclosure inadequate modify respective opinion conclusion base audit evidence obtain date auditor report future event condition cause group cease able continue go concern evaluate overall presentation structure content consolidated financial statement include disclosure consolidated financial statement present underlying transaction event manner consolidated financial statement true fair view asset liability financial position financial performance group compliance german legally require accounting principle oiloftrop tcudorp boehringer ingelheim annual report obtain sufficient appropriate audit evidence financial information entity business activity group express opinion consolidate financial statement group management report responsible direction supervision performance group audit remain solely responsible opinion evaluate consistency group management report consolidate financial statement conformity german law view group position provide perform audit procedure prospective information present management group management report basis sufficient appropriate audit evidence evaluate particular significant assump tion management basis prospective information evaluate proper derivation prospective information assumption express separate opinion prospective infor mation assumption basis substantial unavoidable risk future event differ materially prospective information communicate charge governance matter plan scope time audit significant audit finding include significant deficiency internal control identify audit frankfurt main march kpmg wirtschaftsprfungsgesellschaft original german version sign kneisel krau wirtschaftsprfer wirtschaftsprfer german public auditor german public auditorpage human pharmaceutical animal health oiloftrop tcudorp boehringer ingelheim annual report respiratory disease respiratory disease common chronic obstructive bronchial asthma pulmonary disease copd bronchial asthma bronchial asthma chronic inflammatory disorder air prevalent chronic disease frequent cause way inflammation accompany airway hyperre morbidity premature death worldwide sponsiveness lead narrow airways recurrent episode wheeze breathlessness cough idiopathic pulmonary fibrosis ipf rare disease symptom occur particularly night early severely debilitate ultimately lethal hour morning know asthma trig gere genetic environmental factor allergen copd viral infection unlike copd asthma occur early copd chronic disease lung cause cough childhood present adolescent adults excessive mucus production dyspnea ultimately asthma underestimate easytomanage condi destroy lung tissue alveolus gas exchange tion patient asthma affect lead limitation airflow experience symptom receive maintenance therapy cause shortness breath respiratory symptom put increase risk potentially lifethreatene airflow limitation partially reversible usually asthma exacerbation addition patient adjust worsens time lead disability ultimately death daily live accommodate condition avoid physical symptom excess cough breathlessness exertion daytoday activity negative impact main reason copd stressful patient lung quality life emphysema chronic bronchitis main manifesta tion copd copd cause continuous damage lung result inhale pollutant primarily cigarette smoke factor need consider include indoor outdoor air pollution course copd disease occur second half human life character ise accelerate loss lung function compare mal age occasional sudden worsen symptom function refer acute exacerbation lead downward spiral worsen symptom inactivity product portfolio human pharmaceutical indication brand name active ingredient chronic obstructive spiriva tiotropium bromide maintenance treatment patient pulmonary disease copd spiriva handihaler copd include chronic bronchitis spiriva respimat emphysema maintenance treatment associate dyspnoea prevention exacerbation bronchial asthma spiriva respimat tiotropium bromide addon maintenance bronchodilator treatment patient age year old severe asthma experience severe asthma exacerbation past year spiriva respimat approve use asthma japan usa country label vary country refer local product information chronic obstructive spiolto respimat tiotropium bromide maintenance treatment airflow obstruc pulmonary disease copd stiolto respimat olodaterol tion patient chronic obstructive inspiolto respimat hydrochloride pulmonary disease copd chronic obstructive striverdi respimat olodaterol hydrochloride maintenance treatment patient pulmonary disease copd chronic obstructive pulmonary disease copd reversible bronchospasm combivent respimat ipratropium bromide combination shortacte anticholin associate obstructive salbutamol sulphate ergic betaadrenergic manage airway disease ment reversible bronchospasm associ ate obstructive airway disease patient require bronchodi lator chronic obstructive atrovent ipratropium bromide prevention treatment shortness pulmonary disease copd breath patient chronic obstructive chronic bronchitis pulmonary disease copd mild mod bronchial asthma erate bronchial asthma adulthood childhood supplement betaagonist case acute asthma chronic obstructive airway berodual ipratropium bromide fenoterol prevention treatment symptom disorder bronchodual hydrobromide chronic obstructive airway disorder duovent reversible airflow limitation bron chial asthma especially chronic bronchi tis emphysema boehringer ingelheim annual report respiratory disease continue idiopathic pulmonary fibrosis ipf acute ipf exacerbation define rapid deterioration ipf chronic progressive lung disease associate symptom lung function day week markedly reduce life span affect event occur point course disease people worldwide ipf characterise progre presentation associate high mortality sive scar lung tissue loss lung function patient ipf risk acute ipf exacerbation time development scar tissue call fibrosis time tissue thicken stiffen scar lung lose ability transfer oxygen blood stream vital organ oxygen result individual ipf experience shortness breath rest difficulty cope demand everyday life limited physical capacity product portfolio human pharmaceutical indication brand name active ingredient bronchial asthma berotec fenoterol hydrobromide symptomatic treatment acute asthma attack prophylaxis exerciseinduce asthma bronchiale symptomatic treatment allergic non allergic asthma bronchiale condi tions reversible airway narrow chronic obstructive bronchitis bronchial asthma alesion epinastine hydrochloride prophylactic treatment patient allergic rhinitis flurinol bronchial asthma prophylaxis sympto matic treatment allergic rhinitis idiopathic pulmonary fibrosis ofev nintedanib treatment patient idiopathic ipf pulmonary fibrosis ipf boehringer ingelheim annual report cardiovascular metabolic disease cardiovascular disease leading cause death prevention treatment venous worldwide increase prevalence currently thromboembolism responsible nearly death worldwide key venous thromboembolism vte umbrella term risk factor develop cardiovascular disease presence encompass deep vein thrombosis dvt pulmonary diabete people type diabete time embolism dvt occur thrombus blood clot form likely develop cardiovascular disease people deep vein commonly leg partially com diabetes result life expectancy pletely blocks flow blood thrombus grow year short proper control diabete treata portion break away main clot travel ble risk factor vital prevention cardio circulatory system lung lodge blood clot vascular event artery lung call vte disorder potentially fatal consequence stroke stroke rapidly develop loss brain function cause patient undergo orthopaedic surgery considerable disrupt blood flow affect brain tissue risk develop dvt chronic venous insufficiency ischaemia lack blood supply cause thrombosis pulmonary hypertension develop long term embolism bleed hemorrhagic stroke prevent vte event consequence orthopaedic result affect area brain unable function surgery patient receive kind thromboprophy damage quickly permanent untreated stroke laxis patient suffer vte require anti acute event require emergency diagnosis interven coagulant treatment secondary prevention recurrent tion worldwide stroke lead cause death thromboembolic event longterm disability reverse anticoagulation symptom transient ischaemic attack tia similar anticoagulation therapy offer important benefit patient stroke minute hour risk thromboembolic event rare result permanent neurological damage tia precede situation rapid reversal anticoagulation stroke emergency medical care subsequent preventive medically necessary patient take anticoagulant treatment necessary involve severe car accident need emergency surgery atrial fibrillation atrial fibrillation common sustained heart rhythm condition affect approximately total pop ulation adult develop lifetime patient high risk develop blood clot upper leave heart chamber cause stroke clot break loose travel brain lead fivefold increase risk stroke result million patient worldwide suffer afrelate stroke year patient risk stroke reduce appropri eat anticoagulation therapy product portfolio human pharmaceutical indication brand name active ingredient stroke prevention atrial pradaxa dabigatran etexilate prevention stroke blood clot fibrillation pradaxar patient atrial fibrillation primary prevention venous prazaxa primary prevention venous thrombo thromboembolic event embolic event vte adult elective orthopaedic surgery total hip knee replacement surgery treatment secondary prevention venous throm treatment deep vein thrombosis dvt boembolic event pulmonary embolism secondary prevention recurrent dvt adult specific reversal pradaxa praxbind idarucizumab praxbind specific reversal agent dabigatran etexilate dabigatran indicate adult patient treat pradaxa dabigatran etexilate rapid reversal anticoagulant effect require emergency surgery urgent procedure lifethreatene uncontrolled bleed hypertension micardis telmisartan treatment hypertension reduction cardiovascular morbidity risk myocardial infarction heart mortality prevention attack stroke death cardiovascular cause patient year age old high risk develop major event unable ace inhibitor usa reduction cardiovascular morbidity patient manifest atherothrombotic cardio vascular disease history coronary heart disease stroke peripheral arterial disease patient type diabete mellitus document target organ damage hypertension micardisplus telmisartan treatment hypertension micardi plus hydrochlorothiazide antihypertensive agent low micardis hct blood pressure lower blood pressure reduce risk fatal nonfatal cardio comicardi vascular event primarily stroke myo cardial infarction indicate initial therapy treatment essential hypertension micardisp lus fix dose combination indicate adult blood pressure adequately control telmisartan ypertension twynsta telmisartan amlodipine treatment hypertension micamlo antihypertensive agent initial micardis amlo therapy patient likely need multiple antihypertensive agent achieve micardis duo blood pressure goal usa addon therapy adult patient adequately control blood pressure amlodipine replacement therapy adult patient receive telmisartan amlodipine separate tablet boehringer ingelheim annual report cardiovascular metabolic disease continue hypertension cardiovascular disease hypertension high blood pressure chronic disease blood pressure chronically elevated hypertension major risk factor stroke heart attack heart failure chronic renal failure primary goal anti hypertensive treatment prevent cardiovascular event reduce risk cardiovascular mortality acute myocardial infarction acute myocardial infarction heart attack occur thrombus blood clot suddenly prevent blood flow area heart muscle blood flow restore quickly affect section heart muscle permanently damage heart attack common cause death industrialise country product portfolio human pharmaceutical indication brand name active ingredient acute ischaemic stroke actilyse alteplase fibrinolytic treatment acute ischaemic acute myocardial infarction actilyse cathflo stroke acute myocardial infarction acute acute massive pulmonary massive pulmonary embolism fibrinolytic embolism treatment occlude catheter catheter clearance thrombotic occlusion secondary prevention aggrenox dipyridamole prevention stroke follow initial stroke transient ischaemic asasantin acetylsalicylic acid stroke transient ischaemic attack tia attack tia asasantin retard acute myocardial infarction metalyse tenecteplase fibrinolytic treatment acute myocardial infarction hypertension catapresan clonidine treatment hypertension catapre clonidine hydrochloride catapressan cataprestts hypertension motens lacidipine treatment hypertension boehringer ingelheim annual report cardiovascular metabolic disease continue diabete overall half death people type diabete type diabetes chronic progressive condition associate cause concomitant cardiovascular disease indicate elevated blood sugar level cause longterm high unmet medical need complication treat estimate million death worldwide year link directly longterm addition cardiovascular disease complication effect diabete type diabetes common form diabete include disease account case develop world currently million people nephropathy culminate renal failure require dialysis world live diabetes represent enormous retinopathy potential loss vision burden health care system globally effective pre peripheral neuropathy risk develop foot ulcer vention management strategy estimate potentially require foot leg amputation number case reach million autonomic neuropathy cause gastrointestinal genitourinary cardiovascular symptom addition type diabete major risk factor exual dysfunction cardiovascular disease life expectancy people type diabete high cardiovascular risk decrease average year product portfolio human pharmaceutical indication brand name active ingredient type diabetes mellitus trajenta linagliptin treatment adult type diabetes tradjenta mellitus adjunct diet exercise trazenta improve glycaemic control mono therapy metformin tolerate trayenta contraindicated combination therapy type diabete mellitus jentadueto linagliptin metformin hydrochloride treatment adult type diabete trayenta duo mellitus adjunct diet exercise trajenta duo improve glycaemic control treatment metformin lead sufficient trajentamet control patient treat trajenta linagliptin metformin type diabete mellitus jardiance empagliflozin treatment adult type diabete jardianz mellitus adjunct diet exercise improve glycaemic control reduce risk cardiovascular death adult type diabete mellitus establish cardiovascular disease usa indication december label vary country refer local product information type diabetes mellitus synjardy empagliflozin treatment adult type diabete jardiance duo metformin mellitus adjunct diet exercise hydrochloride improve glycaemic control treatment empagliflozin metformin hydrochloride appropriate usa indication december label vary country refer local product information type diabete mellitus glyxambi empagliflozin linagliptin treatment adult type diabete mellitus adjunct diet exercise improve glycaemic control adult type diabete mellitus empagli flozin linagliptin appropriate treat ment usa indication march label vary coun try refer local product information diabete portfolio collaboration eli lilly company boehringer ingelheim annual report oncology cancer threat global health estimate recently incidence lung cancer million new case cancer diagnose worldwide nonsmoker increase lung cancer poor prognosis million people die cancer nearly global million death year represent nearly death world cancer factsheet com cancer death lung cancer symptom unspecific mon diagnose cancer type lung cancer nearly disease year appear late diagnosis breast cancer nearly colorectal cancer prostate advanced stage disease result dismal cancer stomach cancer prognosis lung cancer patient survive year follow diagnosis lung cancer lung cancer refer malignant abnormal cell growth inside lung cancer disease different lung tissue form cluster tumour com subtype small cell lung cancer sclc nonsmall mon cancer estimate million new case year cell lung cancer nsclc different molecular worldwide smoking primary cause dis genetic aberration mutation present tumour ease contribute case identify focus molecular change specific respective subtype lung cancer target ther apie effective treatment survival benefit time harmful normal cell reduce effect product portfolio human pharmaceutical indication brand name active ingredient nonsmall cell lung cancer giotrif afatinib firstline treatment patient meta nsclc gilotrif static nonsmall cell lung cancer nsclc tumour activate epidermal growth factor receptor egfr mutation treatment patient locally advanced metastatic nsclc squamous histology progress platinum base chemotherapy nonsmall cell lung cancer vargatef nintedanib combination therapy docetaxel nsclc treatment adult patient locally advanced metastatic local nonsmall cell lung cancer nsclc adenocarcinoma tumour histology firstline chemotherapy boehringer ingelheim annual report disease central nervous system mental neurological disease depression par restless leg syndrome rls kinson disease significantly impact patient fami restless leg syndrome rls common neurological disor lie substantial burden society der characterise uncontrollable urge leg primarily occur evening night hour usually parkinson disease accompany unpleasant painful sensa parkinson disease degenerative disorder cen tion leg disturb sleep result daytime tral nervous system patient usually notice motor symptom tiredness sleepiness sensation feel deep like hand tremor shake sign disease leg describe creep crawl aching progress include shake arm leg head motor symptom develop time include stiffness result loss facial expression gradual slow loss motion freeze patient suffer nonmotor symptom associate depression sleep disorder primary symptom result lack neuro transmitter dopamine distinct area human brain infectious disease hiv infectionaid acquire immune deficiency syndrome aid set symp tom infection result damage human immune system cause human immunodeficiency virus hiv untreated infection hiv progressively reduce effectiveness immune system leave individual susceptible opportunistic infection tumour baby infect mother risk get virus preg nancy childbirth breastfeed product portfolio human pharmaceutical indication brand name active ingredient parkinson disease sifrol pramipexole symptomatic treatment idiopathic parkin restless leg syndrome rls mirapex son disease monother mirapexin apy combination levodopa symp tomatic treatment idiopathic moderate pexola severe restless leg syndrome sleep disorder lendormin brotizolam shortterm treatment disorder initiat ing maintain sleep insomnia require pharmacological inter vention indication brand name active ingredient hivaid viramune nevirapine combination therapy hiv infec viramune tion country pre vention mothertochild transmission hiv pregnant woman take antiretroviral therapy time labour prolong release tablet oncedaily dose combination therapy hivaids aptivus tipranavir indicate combination antiretroviral treatment hivinfecte patient administer ritonavir treatmentexperience infect hiv strain resistant protease inhibitor boehringer ingelheim annual report livestock swine infectious respiratory disease infectious enteric disease ingelvac circoflex singledose piglet vaccine enterisol ileitis oral live vaccine control porcine circovirus disease pcvd vaccine ileitis globally prevalent enteric disease swine provide significant reduction mortality acute phase cause lawsonia intracellularis license improve pcvd improve growth rate chronic phase weight gain reduce growth variability associate disease ingelvac circoflex protect minimal disease enterisol ileitis help reduce total anti systemic adverse reaction injection site swelling microbial use pork production gestation lactation ingelvac prrs product license active immunisation respiratory reproductive form porcine reproductive respiratory syndrome prrs ingelvac mycoflex provide proven safety efficacy rapid onset longlaste immunity mycoplasma hyo pneumoniae hyo single dose ingelvac mycoflex contain impranflex adjuvant allow fresh mix e ingelvac ircoflex form flexcombo ingelvac provenza protect multiple iavs strain decrease nasal shed provide protection pig vulnerable product portfolio animal health indication brand name active ingredient infectious respiratory ingelvac circoflex recombinant vaccine active immunisation pig disease porcine circovirus age week porcine circovirus type pcv type reduce mortality clinical sign include weight loss lesion lymphoid tissue associate porcine circovirus disease pcvd addition vaccination show reduce pcv nasal shed viral load blood lymphoid tissue duration viraemia infectious respiratory ingelvac prrs mlv attenuate live vaccine depend product active disease ingelvac prrsflex prrs virus type type immunisation pig age reprocyc prrs porcine reproductive respiratory syndrome virus prrsv infectious respiratory ingelvac mycoflex inactivate vaccine active immunisation pig disease mycoplasma age week reduce lung lesion hyopneumoniae follow infection mycoplasma hyo pneumoniae infectious respiratory ingelvac provenza attenuate live influenza vaccine vaccination pig day age disease laiv old influenza virus strain infectious enteric disease enterisol ileitis attenuate live vaccine active immunisation pig lawsonia age week intestinal lesion intracellularis cause lawsonia intracellularis infection reduce growth variability loss weight gain associate disease boehringer ingelheim annual report livestock cattleruminant cattleruminant business global leader antiparasitic brand ivomec longrange eprinex world renowne parasiticide treat protect graze animal harmful effect internal external parasite zactran treat cattle bacterial pneumonia sheep digital dermatitis infection bovela active immunisation cattle month age term reproductive infectious disease product portfolio animal health indication brand name active ingredient internal external ivomec ivermectin depend formulation product parasite cattle treatment nematode lice mite tick fly lungworm liver fluke internal external longrange eprinomectin longacting theraphase technology develop parasite cattle formulation eprinomectin allow single treatment day long break parasite life cycle effectively reduce parasite burden pasture longrange effective control internal external parasite cattle gastrointestinal roundworm lungworm grub mite internal external eprinex eprinomectin depend formulation product parasite ruminant treatment nematode lice mite tick fly lungworm cattle sheep bacterial cause respiratory zactran gamithromycin depend species indication country disease interdigital registration product treatment dermatitis footrot metaphylaxis control respiratory disease cattle cause key bacteria mannheimia pasteurella histophilus mycoplasma footrot disease sheep cause key bacteria fusobacterium dichelobacter reproductive infectious bovela bovine viral diarrhoea bvd reduce hyperthermia minimise reduc disease cattle type tion leukocyte count cause bovine viral diarrhoea virus bvdv bvdv reduce virus shed viraemia cause bvdv prevent birth persistently infect calf cause transplacental infection boehringer ingelheim annual report livestock cattleruminant continue vaccine pyramidpresponse pande portfolio respiratory reproductive vaccine prevent disease affect livestock metacam nonsteroidal antiinflammatory drug nsaid help minimise loss inflammation tissue dam age animal suffer disease address need maintain profitability concern farm ani mal wellbee product portfolio animal health indication brand name active ingredient infectious respiratory pyramid family multivalent vaccine combi pyramidpresponse family vaccine disease reproductive presponse nation include different modified provide broad coverage bvd type disorder cattle live virus bovine viral diarrhoea ibr brsv mannheimia haemolytica bvd type infectious single dose contain bovine rhinotracheitis ibr parain metastim adjuvant system enhance fluenza bovine respira animal response great protection tory syncytial virus brsv canada bacteria pasteurella multocida metastim register trademark zoetis ervice llc mannheimia haemolytica canic ola grippotyphosa hardjo icterohaemmorrhagiae pomona pain inflammatory metacam meloxicam treatment mastitis lactate cow disorder control pain associate dehorning surgery indicate use calf affect diarrhoea cattle suffer respiratory disease boehringer ingelheim annual report livestock poultry poultry vaccine portfolio consist significant range live inactivate vaccine broiler layer breeder hen provide protection critical viral bacterial disease like avian influenza infectious bronchitis newcastle disease infectious bursal disease egg drop syndrome avian coryza portfolio preventive pro duct help producer worldwide provide safe affordable abundant sustainable highquality poultry meat egg product portfolio animal health indication brand name active ingredient viral bacterial gallimune polyvalent attenuate live vaccination healthy chicken disease poultry gallivac inactivated vaccine contain disease caused include antigen volvac antigen vaccination prevention common disease avian influenza broiler chicken disease responsible newcastle disease avian loss egg production layer coryza egg drop syndrome infectious bronchitis infectious bursal disease gallibacterium anatis infectious bursal disease vaxxitekhvt ibd serotype live marek prevent mortality reduce clinical marek disease disease vector live vhvt sign lesion infectious bursal disease ecombinant virus onset protection week diluent protection extend week reduce mortality clinical sign lesion marek disease onset protection day single vaccination sufficient provide reliable protection risk period newcastle disease avinew live newcastle disease virus broiler chicken day age active vggaavinew strain immunisation newcastle disease reduce mortality clinical sign associate disease future layer future breeder pullet age week prime active immu nisation egg drop cause newcastle disease vaccination inactivated vaccine strain ulster prior beginning lie marek disease prevexxiontm live herpe virus chimera vaccine recommend ovo vacci serotype nation dayold embryonate strain chicken egg protect virulent marek disease newcastle marek newxxitektm hvtnd live marek disease vectore vaccination dayold embryos isease virus serotype contain onedayold chicken effective gene insert newcastle marek disease newcastle disease disease vaccine include diluent boehringer ingelheim annual report veterinary public health vph work government private partner btv pur multistrain vaccine active immunisation improve control eradicating disease footand sheep cattle prevent viraemia reduce clinical mouth disease bluetongue virus rabie sign cause bluetongue virus footandmouth vaccine portfolio work active immunisation cattle sheep pig reduce clinical sign mortality follow exposure footandmouth disease fmd virus rabisin inactivated vaccine rabie available clear colourless suspension injection product portfolio animal health indication brand name active ingredient footandmouth disease aftopor mix inactivated fmd virus fmd vaccine highly potent purify fmd aftovaxpur antigen widest range antigen aftopor aftovaxpur aftobov aftovax vaccine strain oleosa potential marker property allow differentiation infected aftobov oleosa vaccinate animal diva endemic aftovaxpur doe emergency situation aftovaxpur doe suitable emergency ituation abies rabisin rabisin inactivated adjuvanted rabisin active immunisation raboral vrg rabie glycoprotein dog cat reduce mortality clinical raboral vrg vaccinavectored sign rabie infection immunity rabie vaccine demonstrate month vaccina tion show persist revaccination dose raboral vrg oral rabie recombinant vaccine protect raccoon coyote rabie reduce risk exposure rabie human domestic animal sell government agency conduct rabie control program luetongue btv pur mix inactivated bluetongue virus active immunisation sheep prevent virae mia reduce clinical sign cause bluetongue virus serotype andor combination maximum serotype active immunisation cattle prevent virae mia cause bluetongue virus serotype andor reduce clinical sign cause bluetongue virus serotype andor combination maximum serotype onset immunity demonstrate week week sheep btv primary vaccination course btv btv cattle btv btv serotype boehringer ingelheim annual report companion animal horse main horse product focus prevention treat gastrogard ulcergard indicate treatment ment parasite infestation management solution prevention equine gastric ulcer chronic disease vaccine equine portfolio common disease horse gastrogard sup include range flagship product treatment joint ply easytouse oral paste form disease colic respiratory disease pain management choice treatment gastric ulcer launch nutraceutical ulcergard usa preventive choice horse increase risk develop gastric ulcer prascend indicate treatment pituitary par intermedia dysfunction ppid know equine eqvalanzimecterin contain ivermectin lead ingredi cushing disease clinical sign ppid hypertrichiosis ent control wide variety important internal parasite laminitis change body conformation lack perform include bot benzimidazoleresistant small strongyle ance treatment prascend lifelong easytoadminister oral paste eqvalanzimecterin approve adult horse foal young week age vetera vaccine vaccine portfolio include multiple convenient combination disease protection eqvalan duogold zimecterin gold combine ivermectin horse young month age vaccine pro praziquantel ingredient specifically controls tect infectious organism include tapeworm influenza herpe west nile virus tetanus enable customise protection horse limited needle injection product portfolio animal health indication brand name active ingredient pituitary par intermedia prascend pergolide mesylate symptomatic treatment clinical sign associ dysfunction ppid ate pituitary par intermedia dysfunction ppid know equine cushing disease combination vaccine vetera eastern western venezuelan vaccination healthy horse aid common disease encephalomyelitis tetanus west prevention disease cause horse nile virus equine include antigen canada herpes virus equine influenza viruse equine gastric ulcer gastrogard omeprazole treatment prevention gastric ulcer ulcergard prevention recurrence gastric ulcer horse foal week age old internal parasite eqvalan ivermectin treatment prevention parasitic infes zimecterin ivermectin praziquantel tation horse donkey large eqvalan gold small strongyle ascarids eqvalan duo zimecterin gold goldduo include treatment tape worms boehringer ingelheim annual report companion animal pet pet portfolio offer diverse solution heartgard plus contain active ingredient ivermectin important need canine feline health include indus pyrantel soft beef chew give monthly tryleading parasiticide vaccine therapeutic address ivermectin effective prevent deadly heartworm dis major chronic disease heart failure kidney disease hyper ease pyrantel effective treatment control round tension epilepsy osteoarthritis worm hookworm heartgard launch monthly heartworm preventative year frontline leader flea bestselle heartworm preventative world tick control dog cat trust brand animal health frontline continue broadline offer pet owner allinone convenience providing bring innovation category recent launch confidence cat broad possible protection frontline triact feature repellency insecticidal protect cat broadest spectrum internal efficacy diseasecarrye fly insect external parasite include adult flea flea eggs flea larvae decrease risk transmission vectorborne pathogen tick heartworm hookworm roundworm tapeworm nexgard contain active ingredient afoxolaner new class heart treatment term inodilator oral medication treat flea tick dog vetmedin show significantly improve clinical efficacy palatable beefflavoure soft chew sign extend life expectancy dog congestive heart formulation nexgard currently bestselle pet medi failure originating dilate cardiomyopathy valvular insuf cation animal health industry ficiency mitral andor tricuspid regurgitation recent study show preclinically appropriate nexgard spectra combine flea tick efficacy asymptomatic case dilate cardiomyopathy dober afoxolaner nexgard broadspectrum deworme man pinscher valvular insuffi ciency vetmedin significantly ingredient milbemycin oxime beefflavoure delay onset clinical sign congestive heart failure chew nexgard spectra effective treat flea tick protect dog deadly parasites heartworm lungworm gastrointestinal parasite datum file novel combination fipronil permethrin frontline triactfrontect reduce risk transmission babesia canis dermacentor reticulatus ehrlichia canis rhipicephalus sanguineus tick dog jongejan parasite vector datum file datum file product portfolio animal health indication brand name active ingredient antiparasitic caninefeline frontline fipronil frontline indicate treatment external parasite frontline combo fipronilsmethoprene prevention flea tick chew lice frontline plus fipronilpermethrin dog cat aid control frontline triact frontect sarcoptic mange dog frontline plus frontline combo indi cat treatment prevention flea tick chew lice dog cat break flea life cycle prevent development immature stage aids control sarcoptic mange dog frontline triactfrontect indicate treatment prevention flea tick infestation repellent antifeeding activity necessary sandfly bite fly andor mosquito dog antiparasitic canine external nexgard afoxolaner nexgard deliver highly palatable parasite beefflavoure chew kill adult flea indicate treatment prevention flea infestation treatment control tick infestation dog puppy month antiparasitic canine internal nexgard spectra afoxolaner nexgard spectra deliver highly external parasite milbemycin oxime palatable beefflavoure chew kill adult flea indicate treatment prevention flea tick infestation prevent heartworm disease treat control hookworm roundworm whipworm lung worm infestation dog puppy antiparasitic canine internal heartgard plus ivermectin use dog prevent canine heartworm parasite pyrantel disease eliminate tissue stage heartworm larvae month day infection treatment control roundworm hookworm antiparasitic feline internal broadline fipronil smethoprene protect cat broadest spectrum external parasite eprinomectin praziquantel internal external parasite include adult flea flea eggs flea larvae tick heartworm hookworm roundworm tapeworm congestive heart failure vetmedin pimobendan treatment canine congestive heart failure originate dilate cardio myo pathy valvular insufficiency mitral andor tricuspid regurgitation treatment dilate cardiomyopathy preclinical stage asymptomatic increase leave ventricular endsystolic enddiastolic diameter doberman pinscher treatment dog myxomatous mitral valve disease mmvd preclinical stage asymptomatic systolic mitral murmur evidence increase heart size delay onset clinical symptom heart failure boehringer ingelheim annual report companion animal pet continue metacam nonsteroidal antiinflammatory drug nsaid pet vaccine product portfolio include purevax feline available oral suspension tablet injectable vaccine formulate provide effective protection solution dog oral suspension injectable use adjuvant recombitek provide target pro solution cat dog indication include allevia tection dog recombinant technology tion inflammation pain acute chronic mus culoskeletal disorder reduction pain follow e surgery cat indication include alleviation inflammation pain acute chronic musculoskeletal disorder alleviation mild moderate postoperative pain variety formulation offer veteri narian owner flexibility use formulation prefer individual case manage level inflammation pain associate license indication semintra firstever license angiotensin receptor blocker arb veterinary use provide prove convenient safe compliance solution cat cat owner vet semintra available mgml mgml oral solution semintra mgml launch reduc tion proteinuria associated chronic kidney disease ckd cat semintra mgml launch control ustreatment feline systemic hypertension vetlicense product feline hypertension product portfolio animal health indication brand name active ingredient inflammatory metacam meloxicam dog metacam reduce post disease operative pain inflammation follow orthopaedic fracture operation soft tissue surgery cat metacam reduce postopera tive pain inflammation ovario hysterectomy spay operation orthopaedic minor soft tissue surgery alleviation pain inflammation acute chronic muscu loskeletal disorder dog cat chronic kidney disease ckd semintra telmisartan mgml management chronic kidney dis cat ease ckd cat reduction proteinuria associate ckd cat hypertension cat mgml hypertension indicate treatment eucontrol feline systemic hypertension feline vaccines portfolio purevax feline herpes virus purevax fully adjuvantfree feline feline calicivirus vaccine range provide feline panleukopenia virus optimise safety profile adjuvantfree chlamydophila felis protection component recombinant vectore feline leukemia virus powerful immune response adju recombinant vectore rabie virus vant thank innovative canarypox technology felv rabie easy fit cat lifestyle allow e com pliance feline vaccination guideline sustain protection year rabie component canine vaccine portfolio recombitek recombinant vectore canine dis recombitek offer complete line canine temper virus vaccine canine parvovirus prove efficacy distemper canine adenovirus type presence maternal antibody canine parainfluenza virus coronavirus concentrated parvo demonstrate leptospira canicola protection major circulating strain leptospira grippotyphosa cpva leptospira icterohaemorrhagiae prevention disease shed leptospira pomona leptospirosis recombinant borrelia burgdorferi bordetella bronchiseptica target advanced science need adjuvant recombitek lyme vaccine contain ospa nonadjuvant formulation rekombitek oral bordatella effective safe protection easy datum fileboehring ingelheim annual report boehringer sohn ingelheim comparison balance sheet financial data eur million asset december intangible asset tangible asset financial asset fix asset inventory account receivable asset incl prepay expense defer taxis exceed plan asset liquid fund current asset total asset equity liability december shareholder capital group reserve incl balance sheet currency conversion difference group profit equity attributable parent company noncontrolle interest group equity difference capital consolidation provision incl defer taxis liability incl defer income total liability incl defer taxis defer income total equity liability summary select financial datum net sale operating income operating income net sale income taxis income taxis net sale return equity equity ratio cash flow operating activity financial fund personnel expense personnel expense net sale average number employee research development expense expense net sale investment tangible asset depreciation tangible asset boehringer sohn asset december binger strae intangible asset ingelheim germany tangible assets telephone financial asset fax fix asset contact inventory corporate division communication public affair account receivable asset incl prepay expense email pressboehringeringelheimcom defer taxis exceed plan asset internet wwwboehringeringelheimcom liquid fund issue current asset boehringer sohn total asset concept design layout equity liability december mpm corporate communication solution mainz dsseldorf wwwmpmde shareholders capital group reserve incl balance sheet currency conversion difference photo group profit andreas pohlmann andreas reeg equity attributable parent company noncontrolle interest print group equity eberl print gmbh immenstadt difference capital consolidation copyright provision incl defer taxis boehringer sohn liabilities incl defer income right reserve annual report reproduce transmit form mean total liability incl defer taxis defer income electronic photocopy permission write total equity liability boehringer sohn figure party annual report base datum available time financial statement draw summary select financial datum net sale operating income operating income net sale income taxis income taxis net sale return equity equity ratio cash flow operating activity financial fund personnel expense personnel expense net sale average number employee research development expense expense net sale investment tangible asset depreciation tangible asset wwwboehringeringelheimcom annualreportboehringeringelheimcom